

(19)  Canadian Intellectual Property Office
An Agency of Industry Canada

Office de la Propriété Intellectuelle du Canada
Un organisme d'Industrie Canada

(11) CA 2 379 518
(40) 01.02.2001
(43) 01.02.2001

(13) A1

(12)

(21) 2 379 518
(22) 27.07.2000

(51) Int. Cl. 7: C12N 15/53, C12N 9/02,
C12N 11/06, C12N 11/14,
C12Q 1/26, C12P 7/64

(85) 23.01.2002

(86) PCT/EP00/07251

(87) WO01/007573

(30) 199 35 115.5 DE 27.07.1999
100 11 723.6 DE 10.03.2000


(72) HAUER, BERNHARD (DE).
SCHWANEBERG, ULRICH (DE).
SCHMID, ROLF D. (DE).

(71) BASF AKTIENGESELLSCHAFT,
67056, LUDWIGSHAFEN, XX (DE).

(74) ROBIC

(54) SYSTEME DONNEUR D'ELECTRONS POUR ENZYMES ET SON UTILISATION POUR LA TRANSFORMATION BIOCHIMIQUE DE SUBSTRATS
(54) ELECTRON DONOR SYSTEM FOR ENZYMES AND ITS USE FOR THE BIOCHEMICAL CONVERSION OF SUBSTRATES

(57) The invention relates to a novel electron donor system for enzymes with redox properties and to its use in enzyme-catalyzed oxidation reactions, such as the production of omega-hydroxylated fatty acids. The invention further relates to an improved analysis method for fatty acid monooxygenases and to bioreactors and test kits wherein the inventive electron donor system is advantageously used.



BEST AVAILABLE COPY



Office de la Propriété
Intellectuelle
du Canada
Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office
An agency of
Industry Canada

CA 2379518 A1 2001/02/01

(21) 2 379 518

(12) DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION

(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2000/07/27
(87) Date publication PCT/PCT Publication Date: 2001/02/01
(85) Entrée phase nationale/National Entry: 2002/01/23
(86) N° demande PCT/PCT Application No.: EP 2000/007251
(87) N° publication PCT/PCT Publication No.: 2001/007573
(30) Priorités/Priorities: 1999/07/27 (199 35 115.5) DE;
2000/03/10 (100 11 723.6) DE

(51) Cl.Int. 7/Int.Cl. 7 C12N 15/53, C12P 7/64, C12Q 1/26,
C12N 9/02, C12N 11/14, C12N 11/06


(71) Demandeur/Applicant:
BASF AKTIENGESELLSCHAFT, DE

(72) Inventeurs/Inventors:
HAUER, BERNHARD, DE;
SCHWANEBERG, ULRICH, DE;
SCHMID, ROLF D., DE

(74) Agent: ROBIC

(54) Titre : SYSTEME DONNEUR D'ELECTRONS POUR ENZYMES ET SON UTILISATION POUR LA
TRANSFORMATION BIOCHIMIQUE DE SUBSTRATS

(54) Title: ELECTRON DONOR SYSTEM FOR ENZYME AND ITS USE FOR THE BIOCHEMICAL CONVERSION OF
SUBSTRATES



(57) Abrégé/Abstract:

The invention relates to a novel electron donor system for enzymes with redox properties and to its use in enzyme-catalyzed oxidation reactions, such as the production of ω hydroxylated fatty acids. The invention further relates to an improved analysis

Canada

<http://opic.gc.ca> · Ottawa-Hull K1A 0C9 · <http://cipo.gc.ca>

OPIC · CIPO 191

OPIC



(57) Abrégé(suite)/Abstract(continued):

method for fatty acid monooxygenases and to bioreactors and test kits wherein the inventive electron donor system is advantageously used.

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

BERICHTIGTE FASSUNG

(19) Weltorganisation für geistiges Eigentum
Internationales Büro(43) Internationales Veröffentlichungsdatum
1. Februar 2001 (01.02.2001)

PCT

(10) Internationale Veröffentlichungsnummer
WO 01/07573 A1(51) Internationale Patentklassifikation⁷: C12N 15/53, 11/14, 11/06, 9/02, C12Q 1/26, C12P 7/64

(30) Angaben zur Priorität:

199 35 115.5 27. Juli 1999 (27.07.1999) DE
100 11 723.6 10. März 2000 (10.03.2000) DE

(21) Internationales Aktenzeichen: PCT/EP00/07251

(71) Anmelder (für alle Bestimmungsstaaten mit Ausnahme von US): BASF AKTIENGESELLSCHAFT [DE/DE]; D-67056 Ludwigshafen (DE).

(22) Internationales Anmeldedatum: 27. Juli 2000 (27.07.2000)


(72) Erfinder; und

(75) Erfinder/Anmelder (nur für US): HAUER, Bernhard [DE/DE]; Merowingerstrasse 1, D-67056 Fussgönheim (DE). SCHMID, Rolf, D. [DE/DE]; Allmandring 31,

[Fortsetzung auf der nächsten Seite]


(54) Title: ELECTRON DONOR SYSTEM FOR ENZYMES AND ITS USE FOR THE BIOCHEMICAL CONVERSION OF SUBSTRATES

(54) Bezeichnung: ELEKTRONENDONORSYSTEM FÜR ENZYME UND DESSEN ANWENDUNG BEI DER BIOCHEMISCHEN UMSETZUNG VON SUBSTRATEN



(57) Abstract: The invention relates to a novel electron donor system for enzymes with redox properties and to its use in enzyme-catalyzed oxidation reactions, such as the production of ω hydroxylated fatty acids. The invention further relates to an improved analysis method for fatty acid monooxygenases and to bioreactors and test kits wherein the inventive electron donor system is advantageously used.

(57) Zusammenfassung: Die Erfindung betrifft ein neuartiges Elektronendonorsystem für Enzyme mit Redoxeigenschaften, und dessen Verwendung in enzymkatalysierten Oxidationsreaktionen, wie insbesondere der Herstellung ω hydroxylierter Fettsäuren. Die Erfindung betrifft außerdem ein verbessertes Nachweisverfahren für Fettsäuremonooxygenasen, Bioreaktoren sowie Testkits, worin das Elektronendonorsystem vorteilhaft einsetzbar ist.



AA. CHROMOPHORE
AB. HYDROXYLATION
AC... CHROMOPHOROUS
CARBOXYLIC ACID

AD... CHROMOPHOROUS COMPOUND
AE... OXYCARBOXYLIC ACID
AF. DISSOCIATION
AG. UNSTABLE HEMIACETAL

WO 01/07573 A1

WO 01/07573 A1



D-70569 Stuttgart (DE). SCHWANEBERG, Ulrich
[DE/DE]; Uhlandstrasse 15, D-71336 Waiblingen (DE).

Veröffentlicht:

— Mit internationalem Recherchenbericht.

(74) Anwälte: KINZEBACH, Werner usw.; Reitsötter,
Kinzebach & Partner, Sternwartstrasse 4, D-81679
München (DE).

(48) Datum der Veröffentlichung dieser berichtigten
Fassung: 5. April 2001

(81) Bestimmungsstaaten (national): AU, CA, CN, JP, NO,
US.

(15) Informationen zur Berichtigung:
siehe PCT Gazette Nr. 14/2001 vom 5. April 2001, Section
II

(84) Bestimmungsstaaten (regional): europäisches Patent (AT,
BE, CH, CY, DE, DK, ES, FL, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).

Zur Erklärung der Zweibuchstaben-Codes, und der anderen
Abkürzungen wird auf die Erklärungen ("Guidance Notes on
Codes and Abbreviations") am Anfang jeder regulären Ausgabe
der PCT-Gazette verwiesen.

Electron donor system for enzymes and its use for the biochemical conversion of substrates

5 The invention relates to a novel electron donor system for enzymes with redox properties, and to the use thereof in enzyme-catalyzed oxidation reactions such as, in particular, the preparation of ω -hydroxylated fatty acids. The invention additionally relates to an improved detection method for fatty 10 acid monooxygenases, to bioreactors and to test kits in which the electron donor system can advantageously be employed.

The biotechnological use of enzymes with redox properties, such as, for example, monooxygenases, in cell-free reaction systems is 15 always associated with the problem that the use of natural cofactors for providing the necessary redox equivalents (such as, for example, NADH or NADPH) is associated with unacceptably high costs.

20 This also applies to the biotechnological use of cytochrome P450-containing monooxygenases. All P450 enzymes have the common function of transferring oxygen atoms to unactivated aliphatic or aromatic X-H (X = -C, -N, -S) bonds. In addition, P450 enzymes are able to epoxidize the -C=C- double bond. Most P450 systems 25 require for these oxygenation reactions cofactors such as NADPH or NADH as source of electrons. P450 systems are divided into four classes in accordance with the implementation of this electron transfer system (reductase system). Class I P450 enzymes contain as reductase an FAD domain and another Fe-S protein 30 (usually mitochondrial and bacterial P450 enzymes), classe II P450 enzymes have an FAD/FMN reductase (usually ER P450 enzymes) and class III P450 enzymes require no other reducing equivalents; they convert peroxygenated substrates which already contain oxygen. The only P450 enzyme of class IV obtains its electrons 35 directly without a transfer system from NADH.

The functional diversity of the monooxygenations catalyzed by P450 systems of compounds which can often be obtained by chemical means only with difficulty offers an enormous biotechnological, 40 pharmacological and toxicological potential. One important precondition for *in vitro* use of these potentials is the development of suitable expression, purification and, in particular, activity detection systems which permit P450 systems to be characterized and enzyme variants with "improved" 45 properties to be found.

A further important precondition for the use of these P450 monooxygenases, in particular of classes I and II, would be the availability of an electron donor system at reasonable cost.

5 An NADPH cofactor recycling system has been described by Deffner et al., Ann. N.Y. Acad. Sci. (1987) 501, 171. However, on use on the preparative scale, this represents a cost problem and makes reactions carried out in enzyme-membrane reactors more complicated. Alternative electron donors have therefore been
10 sought. One promising route is the electrochemical reduction of P450 enzymes. Estabrook et al. (Methods Enzymol. (1996) 272, 44) were able to determine conversions for six different P450 enzymes using a Co(III) sepulchrone mediator system and Pt electrodes. The activities were, however, about 8-times less than with the
15 reducing equivalent NADPH. In place of the mediator, sodium dithionite (Fang et al., Drug. Metab. Dispos. (1996) 24(11): 1282) was found to be a compound which directly reduces P450 enzymes. In the case of P450 BM-3, the activity was reduced with sodium dithionite by a factor 8150 compared with NADPH; it is presumed
20 that P450 BM-3 is triply reduced by sodium dithionite and thus mostly inactivated.

It is an object of the present invention firstly to provide an efficient, alternative electron donor system at reasonable cost
25 for enzymes with redox properties. It was particularly intended that this system be usable in biochemical conversions in which cytochrome P450-containing enzymes are involved. It was additionally intended to provide an improved detection method for P450 enzymes. A further object of the invention was to provide an
30 improved biotechnological method for the enzymatic transfer of oxygen to organic molecules and, in particular, for the terminal or subterminal hydroxylation of hydrocarbyl compounds having a polar group, such as in particular fatty acids.

35 We have found that these objects are achieved by providing an electron donor system for transferring electrons to enzymes with redox properties, wherein the system comprises an inorganic, non-electrode-bound source of electrons and a mediator which is able to transfer electrons from the source of electrons to the
40 enzyme. It is possible in this connection for the components of the system to be present singly or in a mixture, in carrier-bound or, preferably, non-carrier-bound form.

45 A "non-electrode-bound source of electrons" for the purpose of the invention is able to deliver electrons to the mediator without application of an external voltage between a pair of

electrodes. This entails in particular reduction of the mediator by the source of electrons via a chemical redox reaction.

The electron donor system provided according to the invention can 5 be used in particular for cytochrome P450-containing enzymes such as, for example, the enzymes comprised in the large family of monooxygenases (E.C. 1.14.---). A nonlimiting example which may be mentioned here is the cytochrome P450 monooxygenase BM-3 which can be isolated from *Bacillus megaterium*.

10

In a preferred embodiment of the electron donor system, the latter comprises a mediator with a standard normal potential (for example measured against a calomel electrode; under standard conditions; cf. Creasor et al. below) in the region of less than 15 about -0.4 V. Nonlimiting examples of mediators which may be used according to the invention are cobalt(III) sepulchrate, methylviologen, neutral red, riboflavin, ruthenium triacetate, FMN and FAD, with cobalt(III) sepulchrate being preferred. Cobalt(III) sepulchrate has, for example under standard 20 conditions, a normal potential of -0.54 V (cf. Creasor et al. (1977), *J. Am. Chem. Soc.*, 99, 3181).

The electron donor system according to the invention preferably comprises as source of electrons a metal with a lower standard 25 normal potential than the mediator. A nonlimiting example of the source of electrons which may be mentioned here is metallic zinc. The metal is for this purpose preferably present in a reactive form, i.e. with a large surface area, such as, for example, in powder form.

30

Preferred electron donor systems according to the invention comprise the following combinations of source of electrons and mediator:

35 - Zn/cobalt(III) sepulchrate or
- Zn/neutral red.

The invention further relates to a method for the enzymatic oxidation of, i.e. transfer of oxygen to, a 40 hydrocarbon-containing hydrogen donor molecule (i.e. an oxidizable compound), which comprises incubating the hydrogen donor molecule in a reaction medium comprising the oxygen-transferring enzyme and an electron donor system complying with the above definition, in the presence of oxygen under 45 reaction conditions.

An "oxidation" for the purpose of the present invention relates to enzyme-catalyzed oxidation reactions in the widest sense. In particular, the term comprises oxidation reactions which are catalyzed by enzymes from the class of monooxygenases

5 (E.C.1.14.---) and, in particular, cytochrome P450 enzymes. These oxidation reactions comprise:

- a) carbon oxidations at saturated or unsaturated, aliphatic or aromatic carbon atoms, e.g. hydroxylations and epoxidations;
- 10 b) sulfur oxidations;
- c) nitrogen oxidations;
- d) oxidative dealkylations; and
- e) oxidative dehalogenations.

15 The hydrogen donor molecule is preferably selected from compounds of the formula



20 in which

R is a straight-chain or branched, preferably straight-chain, alkyl radical with 8 or more carbon atoms, such as, for example, 10 to 30 carbon atoms, and

25

X is a polar group capable of forming hydrogen bonds, preferably a carboxyl, amide, nitrile, sulfate, sulfone, amine or hydroxyl group.

30 A preferred variant of the above method relates to the enzymatic preparation of terminally or subterminally (i.e. in position ω -1 to ω -4) hydroxylated fatty acids, which comprises

- a) converting a hydroxylatable fatty acid or a hydroxylatable fatty acid derivative in the presence of an electron donor system complying with the above definition using a cytochrome P450 monooxygenase and oxygen; and
- 35 b) isolating the hydroxylated product(s).

40

The ω -hydroxylatable (i.e. terminally or subterminally hydroxylatable) fatty acid or its derivative is according to the invention preferably selected from or derived from terminally saturated, branched or unbranched fatty acids with 8 or more, 45 e.g. more than 10 carbon atoms, in particular C₁₂ - C₃₀ fatty acids.

Nonlimiting examples of hydroxylatable fatty acids according to the invention which should be mentioned are: caprylic, pelargonic, undecanoic, lauric, tridecanoic, myristic, pentadecanoic, palmitic, margaric, stearic, nonadecanoic, 5 arachic, behenic, lignoceric, cerotic and melissic acids.

Examples of suitable fatty acid derivatives are C₁-C₄-alkyl esters, amides or anhydrides with, preferably, short-chain, in particular C₁-C₄-carboxylic acids.

10

The enzyme preferably used in the methods according to the invention described above is a cytochrome P450 monooxygenase selected from:

- cytochrome P450 monooxygenases of the enzyme class

15 E.C. 1.14.-.-, in particular from the CYP102 P450 family, or of eukaryotic or prokaryotic, in particular bacterial, origin, and preferably the wild-type enzyme which can be isolated from *Bacillus megaterium* (DSM 32T); or

- a mutant thereof.

20

A preferred group of mutants is derived from cytochrome P450 monooxygenase BM-3 from *Bacillus megaterium* with an amino acid sequence as shown in SEQ ID NO: 35, which has at least one functional mutation in one of the following amino acid sequence 25 regions: 24-28, 45-51, 70-72, 73-82 (helix 5), 86-88 (helix 6), 172-224 (F/G loop) and 352-356 (β strand 8); and functional equivalents of these mutants.

A "functional mutation" for the purpose of the present invention 30 comprises an amino acid replacement in the stated sequence regions, which leads to a mutant which is still able to catalyze one of the abovementioned oxidation reactions such as, for example, hydroxylations.

35 Particularly preferred according to the invention are P450 BM-3 monooxygenase mutants, each of which comprise at least one functional mutation in the amino acid sequence regions 86-88, 172-224, 73-82, 45-51, 24-28, 70-72 and 352-356 (as shown in SEQ ID NO: 35), singly or in combination.

40

It is possible in particular for an amino acid substitution to be present in at least one of positions 26, 47, 72, 74, 87, 188 and 354 as shown in SEQ ID NO: 35 of the wild-type enzyme.

45 Thus, for example, Phe87 can be replaced by an amino acid with an aliphatic side chain, such as, for example, Ala, Val, Leu, in particular Val or Ala; Leu188 can be replaced by an amino acid

with an amine or amide side chain, such as, for example, Asn, Gln, Arg or, in particular, Lys, or amino acids such as Ala, Gly, Ser and Trp; Ala74 can be replaced by another amino acid with an aliphatic side chain, such as, for example, Val and, in particular, Gly; Arg47 can be replaced by an amino acid with a cyclic side group, such as, for example, His, Tyr or, in particular, Phe; and Val26 can be replaced by an amino acid with a hydroxyl side group, such as, for example, Ser or, in particular, Thr. For example, Ser72 can be replaced by an amino acid with an aliphatic side chain, such as, for example, Ala, Val, Leu, Ile and, in particular, Gly, and Met354 can be replaced by an amino acid with a hydroxyl side group, such as, for example, Ser or, in particular, Thr.

15 Examples of mutants are:

- a) F87V;
- b) F87A, L188K;
- c) F87V, L188K;
- d) F87A, L188K; A74G;
- 20 e) F87V, L188K, A74G;
- f) F87A, L188K, A74G, R47F;
- g) F87V, L188K, A74G, R47F;
- h) F87A, L188K, A74G, R47F, V26T; or
- i) F87V, L188K, A74G, R47F, V26T;
- 25 k) V26T,
- l) R47F,
- m) S72G,
- n) A74G,
- o) F87A
- 30 p) L188z, in which z is K, R, W, Q, N, G, A or S, and
- q) M354T;

and functional equivalents thereof.

35 Suitable mutants are also described, for example, in the earlier DE-A-100 11 723, which is incorporated herein by reference.

The mutants and functional equivalents employed may moreover show an "altered substrate profile" by comparison with the wild-type 40 enzyme.

An "altered substrate profile" means for the purpose of the present invention in particular:

- a) a change in the reactivity, such as, for example, an increase 45 in the specific activity (expressed as nmol of substrate converted/minute/nmol of P450 enzyme) and/or at least one kinetic parameter selected from Kcat, Km and Kcat/Km, for example by at

least 1%, such as, for example, 10 to 1000%, 10 to 500%, or 10 to 100%, of the mutant for at least one oxidizable substrate compared with the wild-type enzyme; and/or

b) a change in the regioselectivity, such as, for example, a 5 shift of the preferred position for the oxidation reaction; this may entail, for example, a shift of the preferred terminal or subterminal (ω -1, ω -2, ω -3, ω -4, in particular ω -1 to ω -3) hydroxylation position on at least one hydroxylatable carboxylic acid or one hydroxylatable derivative of an aliphatic carboxylic 10 acid. The alteration of the substrate profile may moreover be expressed over the entire size range (i.e. C₈-C₃₀) or only in part-regions, for example for C₈-C₁₂-, C₁₀-C₁₂-, C₁₂-C₃₀-, C₁₂-C₂₅- or C₁₂-C₂₀ carboxylic acids or for individual carboxylic acids 15 from these part-ranges.

15

"Functional equivalents" also mean according to the invention mutants which have in at least one of the abovementioned sequence positions an amino acid substitution other than that specifically mentioned but still lead to a mutant which, just like the 20 specifically mentioned mutant, catalyzes one of the oxidation reactions defined above.

Functional equivalence also exists in particular when the alterations in the reactivity pattern are in qualitative 25 agreement.

"Functional equivalents" also include, of course, P450 monooxygenase mutants which are obtainable in the same way as the specifically mentioned P450 BM3 mutants by mutation of P450 30 enzymes from other organisms. For example, it is possible by comparing sequences to establish ranges of homologous sequence regions. It is then possible, with the modern methods of molecular modeling, to undertake equivalent mutations influencing the reaction pattern based on the specific requirements of the 35 invention.

"Functional equivalents" likewise include the mutants obtainable by one or more additional amino acid additions, substitutions, deletions and/or inversions, it being possible for said 40 additional changes to occur in any sequence position as long as they lead to a mutant with an "altered substrate profile" in the above sense.

Mutants which are preferably employed comprise a mutation in 45 position 87 and are selected from the mutations F87A or F87V, which optionally has at least one other of the following mutations: L188K, A74G, R47F and V26T. Particular preference is

given to the one-fold mutant F87A and the five-fold mutant F87A, L188K, A74G, R47F, V26T (amino acids indicated in the one-letter code; original amino acid to the left of the stated position; new amino acid to the right of the stated position).

5

The above methods are preferably carried out using the zinc/Co(III) sepulchrate electron donor system.

In a preferred embodiment of the method, the conversion was
10 carried out in the presence of chloride ions.

The presence of a hydrogen peroxide-cleaving enzyme, e.g. catalase, may also be advantageous.

15 The invention further relates to a bioreactor for use for the enzymatic transfer of oxygen to a hydrocarbon-containing hydrogen donor molecule and, in particular, to the use for producing ω -hydroxylated fatty acids, which comprises an immobilized monooxygenase (e.g. immobilized on a carrier material, e.g. DEAE 20 650M or Super Q650M) and an electron donor system complying with the above definition in a liquid reaction medium. The specific design of the reactor is based on conventional expert knowledge.

The invention further relates to a detection method for fatty
25 acid monooxygenases, which comprises

a) incubating an analyte suspected of having enzymic activity with an ω -hydroxylatable fatty acid or fatty acid derivative which has a terminal fluorophore or chromophore which can be
30 eliminated, in the presence of an electron donor system complying with the above definition; and

b) determining the elimination of the fluorophore or chromophore qualitatively or quantitatively.

35

A suitable analyte is, for example, a cell homogenate, e.g. of a bacterial strain. It is possible to screen for example collections of strains for enzyme activity using the detection method according to the invention.

40

The reaction in this case is preferably carried out in the presence of a hydrogen peroxide-cleaving enzyme and, where appropriate, in the presence of chloride ions.

Examples of suitable fluorophores and chromophores are phenols, catechols, hydroxycoumarins such as umbelliferone, phenoxazines and, in particular, resorufin.

5 Setting of the optimal parameters for the methods for the enzymatic conversions and detection reactions described above is directly possible by taking account of the instructions in the following experimental section. Thus, for example, without being restricted thereto, a cobalt(III) sepulchrate concentration of 10 more than 0.1 mM, such as, for example, 0.5 to 1.0 mM, is particularly advantageous; likewise a pH of about 8 to 8.5; a zinc concentration of more than about 2 mg/ml, such as, for example, about 5 to 50 mg/ml. The hydrogen peroxide-cleaving enzyme can be employed for example in amounts of about 10 to 15 5000 U/ml.

Finally, the invention further relates to a test kit, in particular for carrying out the above detection method for carboxylic acid monooxygenases, comprising an electron donor 20 system complying with the above definition.

The diverse possible uses of the present invention are explained further in the following sections.

25 Catalyzed reactions of P450 systems and examples of industrial applications in fine chemicals synthesis

In organisms, cytochrome P450 enzymes serve inter alia for ergosterol synthesis, the biosynthesis of insect hormones and 30 phytohormones, the development of ripeness in fruit, odor and color in plants, the biosynthesis of glucocorticoids and mineralocorticoids, the aromatization of androgens to estrogens, the metabolism of retinoids to regulate normal and epithelial growth/differentiation, arachidonic acid metabolism to form 35 prostaglandins, leukotrienes and thromboxanes and the formation of vasoactive products. In addition, they serve to activate and detoxify xenobiotic substances.

P450 enzymes belong to the so-called phase I enzymes which 40 prepare, by oxygenations, compounds which are insoluble in water or of low solubility for further metabolism. Phase II enzymes serve for this purpose, such as glutathione transferases, N-acetyltransferase or sulfotransferase, which add a polar group onto the former hydroxylated or epoxidized compounds. This makes 45 these metabolites soluble in water and thus bioavailable. The diversity of reactions catalyzed by cytochrome P450 enzymes are summarized below and discussed in relation to their economic and

10

functional importance. Table 1 shows a summary, broken down into selected families.

Table 1

5

P450 family	Reactions of P450 enzymes
CYP1-3	Metabolization of xenobiotic substances; CYP1: PCB, PAH, dioxins, aflatoxins; CYP2: plant toxins, pesticides; CYP3: cyclosporins, erythromycin, also involved in steroid metabolism
CYP4, CYP52, CYP102	CYP4, CYP52, CYP102: terminal and/or subterminal oxidation of fatty acids CYP4: oxidation of eicosanoids (prostaglandins, leukotrienes and thromboxanes)
CYP11, CYP17, CYP21	Biosynthesis of gluco- and mineralocorticoids; CYP11: 11 β -hydroxylases, hydroxylation of deoxycorticosterone or deoxycortisol; CYP17: steroid 17 α -hydroxylase; CYP21: steroid 21-hydroxylase
CYP19	Conversion of steroids into estrogens; aromatase
CYP27	Cholesterol 27-hydroxylase

The P450 enzymes of the CYP1-3 enzyme families are mainly responsible for the metabolism of xenobiotic substances; the oxidative reactions occurring therein are divided up hereinafter into C, S and N oxidations, dealkylation and dehalogenation.

a) C oxidations

30

P450 enzymes hydroxylate or epoxidize unactivated C-H bonds and/or C=C double bonds in aliphatic and aromatic systems. The metabolites which are formed are frequently toxic, such as the neurotoxin 2,5-hexanedione, or carcinogenic such as DNA-alkylating epoxides (e.g. styrene oxide). In addition, nitrosamines and benzopyrenes C-oxidized by P450 enzymes have carcinogenic effects.

Drugs such as barbiturates and phenobarbitals are likewise converted by P450 enzymes into their active form. The hydroxylation of unactivated -C-H bonds is one of the most useful biotransformation reactions, because competition from chemical methods is rare. In contrast to free-radical reactions, biohydroxylation reactions on C atoms show the following activity sequence: secondary> tertiary> primary. Well-known methods carried out industrially are the hydroxylation of progesterone at position 11 α by *Aspergillus niger*, which made about half of the

11

37 conventional steps unnecessary, and the 7β -hydroxylation of 3α -hydroxy- 5β -cholic acid by *Fusarium equiseti*. The product ursodeoxycholic acid is able to dissolve cholesterol and is employed in the treatment of gallstones. In asymmetric synthesis, 5 biotransformations are used inter alia for synthesizing β -hydroxybutyric acid, a starting material for vitamin syntheses (α -tocopherol), flavorings, antibiotics (calcimycin) and chiral branched epoxidized alkenes.

10 b) N-Oxidation / S-oxidation

P450 enzymes hydroxylate arylamines and acetylated amines, such as benzidine, 4-biphenylamine and 2-acetaminofluorene and comparable heterocycles produced on charring of foodstuffs, on 15 the N atom. Further acetylation or sulfonation of the hydroxyl groups produces electrophilic substances with high carcinogenic activity.

Aryl and alkyl thioethers are oxidized by P450 monooxygenases 20 directly on the S atom to sulfoxides. However, the oxidation frequently does not stop at the sulfoxide stage; many sulfoxides are oxidized further to the corresponding sulfone compounds, which often have cytotoxic effects. Microbial oxidations of chiral dithioacetals take place with a high enantiomeric excess 25 using *Corynebacterium equi* and *Helminthosporium* sp.

c) Oxidative dealkylations

P450 enzymes also catalyze oxidative O-, N- and S-dealkylation. 30 Examples of these important reactions are the O-dealkylation of codeine, mescaline, phenacetin, the N-dealkylation of ephedrine, methamphetamine, aminopurine and the S-dealkylation of 6-methylthiopurine to 6-methylpurine.

35 d) Oxidative deamination

P450 enzymes also catalyze the oxidative deamination of amines. This reaction mainly has a detoxifying function for the organism. Histamine, norepinephrine and mescaline inter alia can be 40 deaminated in this way.

e) Oxidative dehalogenation

Many halogenated alkanes and alkenes form after hydroxylation at a -C-H bond an unstable intermediate which dissociates into an 5 aldehyde or ketone and H-Hal. Examples are the oxidation of ethylene dibromide to 2-bromoacetaldehyde and the oxidation of chloroform to phosgene. Mono- and dihalogenated methane forms metabolites whose cytotoxicity is only low compared with the trihalogenated chloroform.

10

A mechanistic description of the types of P450 reactions which have been presented is to be found in the review article by Koymans et al., in *Xenobiotica*, (1993) 23(6):633.

15 In vivo / in vitro use of P450 monooxygenases for the synthesis of fine chemicals:

In contrast to microbial biotransformation, the use of recombinantly expressed P450 monooxygenases for synthesizing fine 20 chemicals is confined, despite an enormous potential, to a few *in vivo* methods such as the preparation of dicarboxylic acids as intermediates for odorants, steroids such as progesterone and subterminally hydroxylated saturated and unsaturated fatty acids as precursors of fragrances (lactones), polymers and dosage forms 25 for medicines.

The use of P450 monooxygenase enzymes *in vitro* for the synthesis of fine chemicals has not to date been disclosed in the literature. In order to use P450 monooxygenases for synthesizing 30 fine chemicals, it is necessary for expression systems to be available which permit functionally active P450 to be expressed in high yields beyond species boundaries. In addition, the enzyme must have sufficiently high activity and stability (temperature stability, solvent stability, oxidation stability). The produced 35 metabolites ought not to be toxic for the protein and the host. For class I and class II in addition a suitable cofactor recycling system ought to be available. The present invention creates the conditions for this.

40 The P450 BM-3 monooxygenase system

P450 BM-3 (CYP102) was expressed with functional activity in *E. coli*, and characterized, for the first time in 1986 as third P450 monooxygenase from *Bacillus megaterium*. With a molecular weight 45 of 118 kDa, P450 BM-3 was the first known water-soluble natural fusion protein which contains all three domains (FAD, FMN, P450) in a single polypeptide chain. Crystallization of the P450 domain

13

without substrates was achieved in 1993 (Ravichandran et al., Science (1993) 261, 731), and with substrate was achieved in 1997 (Li et al. Nature Structural Biology (1997), 4(2): 140). P450 BM-3 serves, because of its sequence homology to eukaryotic P450s 5 and with the lack of eukaryotic P450 crystal structures, as preferred structural model for these P450 enzymes.

P450 BM-3 is a fatty acid hydroxylase which subterminally hydroxylates carboxylic acids, alcohols, amides, alkylammonium 10 compounds from chain length C12 to C22. The regiospecificity of the hydroxylation depends, as shown in Table 2, greatly on the chain length of the fatty acid.

Table 2

15

	Substrates	ω-Hydroxylation [%]	ω-1 Hydroxylation [%]	ω-2 Hydroxylation [%]	ω-3 Hydroxylation [%]
20	Lauric acid (12:0)	-	48	26	26
	Myristic acid (14:0)	-	58	21	21
25	Palmitic acid (16:0)	-	20	48	31

The invention is now explained in more detail with reference to the appended figures and to the following examples which relate to the use of the donor system according to the invention to the 30 hydroxylation of fatty acids using P450 enzymes. In this connection

Figure 1 shows the P450 BM3 cloning scheme for the example of pCYTEXP1;

35

Figure 2 shows the principle of the spectroscopic P450 detection according to the invention;

Figure 3 shows the absorption spectrum for the reduction of 40 cobalt(III) sepulchrate with Zn powder in Tris/HCl, 0.2 M, pH 8.2; dotted line Co(III) sepulchrate oxidized; full line Zn/Co(III) sepulchrate reduced;

Figure 4 shows the change in absorption on conversion of 12-pNCA 45 by P450 BM-3 F87A with Zn/Co(III) sepulchrate in Tris/HCl, 50 mM, pH 8.2, 0.25 M KCl;

14

Figure 5 shows an outline of the electron transfer route from Zn/Co(III) sepulchrate to P450 with shunt reaction pathway and pNCA as substrate;

5 Figure 6 shows the conversion of 12-PCA by P450 BM-3 F87A and Zn/Co(III) sepulchrate in Tris/HCl, 50 mM, pH 8.2, 0.25 M KCl with and without addition of catalase;

10 Figure 7 shows the effect of the Tris/HCl and potassium phosphate buffer mixtures on the reduction of p-nitrophenolate in the presence of P450 BM-3 F87A and Zn/Co(III) sepulchrate;

15 Figure 8 shows (A) 12-pNCA conversion by P450 BM-3 F87A as a function of the Co(III) sepulchrate concentration; (B) the effect of Co(III) sepulchrate on the activity of P450 BM-3 F87A in the presence of substrate;

20 Figure 9 shows the 12-pNCA conversion as a function of the amount of zinc powder employed in the presence of 0.5 mM Co(III) sepulchrate;

25 Figure 10 shows the remaining P450 BM-3 F87A activity after incubation with various concentrations of hydrogen peroxide without substrate for 5 min.

Reference Example 1: Microbiological methods

1. Microorganisms and plasmids, chemicals and enzymes

30 The bacterium *Bacillus megaterium* was purchased from the DSMZ collection of strains (32^T, Braunschweig, Germany), the *E.coli* strains DH5 α , JM105 and JM109 were purchased from Clontech (Heidelberg, Germany) and XL1-Blue was purchased from Stratagene (Heidelberg, Germany). The strain W3110 was obtained from the Institut für Bioverfahrenstechnik (Stuttgart, Germany). The *E.coli* strain DH5 α (supE44, lacU169 [80lacZ M15] hsdR17 recA1 endA1 gyrA96 thi-1 relA1) was, unless otherwise mentioned, used for the cloning work described below. The plasmids used were 40 pCYTEXP1 with the temperature-inducible P_{RP1} promoter system of bacteriophage λ (Belev T.N., et al., Plasmid (1991) 26:147) and pASK-IBA1CA with tetracycline promoter (Schmidt, T.G.M., et al., J. Chromatogr. A (1994) 676:337; Schmidt, T.G.M. et al., J.Mol.Biol. (1996) 255:753). The strains and plasmids used in 45 this work for heterologous expression of P450 BM-3 are summarized in Table 3, where pT indicates the origin of the P450 BM-3

15

constructs from the pCYTEXP1 plasmid and pA indicates the origin of the pASK-IBA1CA plasmid.

Table 3

	E.coli strain/plasmid insert construct	expressed protein
5	DH5 α /pT-USC0BM3, W3110/pT-USC0BM3	P450 BM-3
10	DH5 α /pT-USC1BM3, JM105/pT-USC1BM3, JM109/pT-USC1BM3, W3110/pT-USC1BM3	P450 BM-3His ₆
15	DH5 α /pT-USC1BM3F87A, JM105/pT-USC1BM3F87A, JM109/pT-USC1BM3F87A, W3110/pT-USC1BM3F87A XL1-Blue/pT-USC1BM3F87A	P450 BM-3His ₆ F87A Mutant
20	DH5 α /pT-USC2BM3, W3110/pT-USC2BM3	P450 BM-3Glu ₆
25	DH5 α /pT-USC3BM3, W3110/pT-USC3MB3	P450 BM-3Arg ₆
30	DH5 α /pA-USC4BM3, JM105/pA-USC4BM3, JM109/pA-USC4BM3, W3110/pA-USC4BM3	P450 BM-3Strep

20 Unless otherwise mentioned, all the chemicals were purchased from Fluka Chemie (Buchs, Switzerland) and all the enzymes were purchased from New England Biolabs (Beverly, USA) or Boehringer Mannheim (Penzberg, Germany).

25 2. Culture media

All the complex media originated from Difco (Augsburg, Germany).

a) Nutrient medium (complete medium for *Bacillus megaterium*)

30	Peptone	5.0 g
	Bacto beef	3.0 g
	Bacto peptone	5.0 g
	Agar	15 g (only for plate culture)
	MnSO ₄ *H ₂ O	10 mg
35	H ₂ O	ad 1000 ml

Glycerol culture

Glycerol (86%)	500 μ l
Culture(OD ₅₇₈ = 1.0)	500 μ l

40 b) Luria-Bertani-Amp (LB-Amp, complete medium for *E. coli*)

40	Tryptone	10.0 g
	NaCl	5.0 g
	Yeast extract	5.0 g
45	Agar	20.0 g (only for plate culture)
	Ampicillin	100 g/ml
	H ₂ O	ad 1000 ml

3. Cultivation of the *E. coli* strains and of *Bacillus megaterium*a) Shaken flask experiments

5 *Bacillus megaterium* was cultivated in the nutrient medium at 30°C, and the recombinant *E. coli* strains (DH5α, JM105, JM109, XL1-Blue, W3110) were cultivated in LB-Amp medium at 37°C. For this purpose, in each case one colony was transferred by an inoculating loop from an agar plate into 10 5 ml of LB-Amp. After cultivation at 30°C (*Bacillus megaterium*) and 37°C (*E. coli*) shaking at a rate of 220 rpm for about 18 h, 400 ml of medium in a 2 l flask were inoculated with 4 ml of culture. Induction of P450 expression in *E. coli* took place after the OD₅₇₈ had reached between 0.8 15 and 1.0 by a heat-shock induction at 42°C for three to four hours in the case of the pT plasmid constructs or by adding anhydrotetracycline (final concentration 0.4 mg/l) in the case of the pA-USC4BM3 plasmid and incubating at 30°C for 14 hours.

20 b) 30-l batch fermentations

25 The expression cassette pT-USC1BM3, the host DH5α and a bioengineering fermenter type LP351 were employed, with aeration at 3.5 l/min, a stirring speed of 300 rpm at 37°C in LB-Amp medium with an initial pH of 7.5, for preparative P450 BM-3 production. In order to avoid foaming and to increase yields, 2.0 ml of sterile Contraspum 210 (ZSchimmer & Schwarz, Lahnstein, Germany) and 0.1 mg/l FeCl₃ were added 30 before inoculating the LB-Amp medium (Nishihara et al. 1997). Inoculation took place by adding two 400 ml shaken flask cultures (OD₅₇₈ = 0.8-1.0; section a)). After the OD₅₇₈ in the fermenter reached 1.0, P450 production took place by heat-shock induction by increasing the temperature from 37°C 35 to 42°C for three to five hours. P450 BM-3 or the mutant F87A was expressed in *E. coli* DH5α in yields of from 36 to 48 mg/l of fermenter broth. The *E. coli* culture was concentrated from 30 liters to 2 liters by crossflow filtration using a Millipore application (Eschborn, Germany) 40 with a Filtron (Dreieich, Germany) Centrasette OMEGA (0.3 μm) membrane. After centrifugation at 9200 g for 20 min, the cells were resuspended in potassium phosphate buffer (50 mM, pH 7.5) or Tris/HCl buffer (50 mM, pH 7.5), aliquoted in twelve 50 ml Falcon tubes (Greiner) and frozen at -20°C 45 until used further.

Reference Example 2: Synthetic oligonucleotides

All the primers were prepared by ARK Scientific GmbH Biosystems (Dusseldorf, Germany). Only the primers for the point mutation 5 and for isolating the P450 BM-3 gene from the genomic *Bacillus megaterium* DNA were purified by HPLC.

a) Oligonucleotides for genomic *Bacillus megaterium* DNA

10 B1) 5'-GTGAAAGAGGGATCCCATGACAATTAAAGAAATGCC-3'
 (SEQ ID NO: 1)
 B2) 5'-GCCTCTGGATCCTTACCCAGCCCACACGTCTTTGCG-3'
 (SEQ ID NO: 2)

15 b) Primers for sequencing

	R0_5	5'-GTACGTGATTTGCAGGAG-3'	(SEQ ID NO: 3)
	R1	5'-GGCTATCATGCGATGATGGT-3'	(SEQ ID NO: 4)
20	R1_5	5'-CCCAGCTTATGATGAAAAC-3'	(SEQ ID NO: 5)
	R2	5'-GGAAAAGATCCAGAAACGGG-3'	(SEQ ID NO: 6)
	R2_5	5'-GTCGGCATGGTCTAAACG-3'	(SEQ ID NO: 7)
	R3	5'-ATTCCTCAGCTTCACCGTGA-3'	(SEQ ID NO: 8)
	R3_5	5'-CTTGGCGGTATTCTTCAC-3'	(SEQ ID NO: 9)
	R4	5'-ATTGCAACCGCAGGTCGCAA-3'	(SEQ ID NO: 10)
25	R4_5	5'-CTGGGCTACTACGTATC-3'	(SEQ ID NO: 11)
	R5	5'-TTCAATTGTCGACAGCGCC-3'	(SEQ ID NO: 12)
	R5_5	5'-GAAGGAGATCATTAGGTG-3'	(SEQ ID NO: 13)
	R6	5'-TCGCGCAATGGCTGCTAAAA-3'	(SEQ ID NO: 14)
	R6_5	5'-CGATTCTTCATCACCTC-3'	(SEQ ID NO: 15)
30	R7	5'-CTGCCAAAAGACCCCTGAAAC-3'	(SEQ ID NO: 16)
	L1	5'-ACCATCATCGCATGATAGCC-3'	(SEQ ID NO: 17)
	L2	5'-CCCGTTCTGGATTTTCC-3'	(SEQ ID NO: 18)
	L3	5'-TCACGGTGAAGCTGAGGAAT-3'	(SEQ ID NO: 19)
	L4	5'-TTGCGACCTGCGGTGCAAAT-3'	(SEQ ID NO: 20)
35	L5	5'-GGCGCTGTCGACAAATTGAA-3'	(SEQ ID NO: 21)
	L6	5'-TTTTAGCAGCCATTGCGCGA-3'	(SEQ ID NO: 22)
	L7	5'-GTTTCAGGGTCTTTGGCAG-3'	(SEQ ID NO: 23)

c) Oligonucleotides for tags at the C terminus

40 A1) 5'-GTGAAAGAGGGATCCCATGACAATTAAAGAAATGCC-3'
 (SEQ ID NO: 24)
 A2) 5'-CGGAATTCTAACGACGACGACGACGCCAGCCCACACG-3'
 (SEQ ID NO: 25)
 45 G1) 5'-GTGAAAGAGGGATCCCATGACAATTAAAGAAATGCC-3'
 (SEQ ID NO: 26)
 G2) 5'-CGGAATTCTATTCTTCTTCTTCCCCAGCCCACACG-3'

18

(SEQ ID NO: 27)

H1) 5'-GTGAAAGAGGGATCCCATGACAATTAAAGAAATGCC-3'

(SEQ ID NO: 28)

H2) 5'-CGCAATTCTTAATGATGATGATGATGCCAGCCCACACG-3'

5 (SEQ ID NO: 29)

S1) 5'-GTCTCAGCGTGAGACCCCCAGCCCACACGTCTTGCC-3'

(SEQ ID NO: 30)

S2) 5'-GTGAAAGAGGTCTCCAATGACAATTAAAGAAATGCC-3'

(SEQ ID NO: 31)

10

d) Primers for P450 BM-3 F87A point mutants

F87A1 5'-GCAGGAGACGGGTTGGCCACAAGCTGGACGCATG-3'

(SEQ ID NO: 32)

15 F87A2 5'-CATGCGTCCAGCTTGTGGCCAACCCGTCTCCTGC-3'

(SEQ ID NO: 33)

Reference Example 3: Genetic engineering methods

20 1. Isolation and precipitation of genomic *Bacillus* DNA and plasmid DNA from *E. coli*

To isolate the genomic DNA from *Bacillus megaterium* by phenol/chloroform extraction, the cell pellet from 200 ml of 25 culture supernatant ($OD_{578} = 1.2$) was resuspended in 20 ml of lysozyme mix (18 mg of lysozyme, 50 mM EDTA, 50 mM NaCl, 30 mM Tris/HCl, pH 8.0) and shaken at 220 rpm and 37°C for 30 minutes. After addition of 2 ml of SDS (10% (m/v)), incubation was continued at 37°C and 220 rpm for 60 minutes. Cell detritus was 30 removed by extraction three times with a chloroform/isoamyl alcohol mixture (Roth, Karlsruhe, Germany) and once with phenol. The genomic DNA is precipitated by adding 10% (v/v) 3 M NaAc, pH 4.8 and 60% (v/v) isopropanol, rolled up on a glass rod, transferred into a Corex tube and centrifuged at 32,570 g. After 35 washing with 70% ethanol three times, the DNA is dried under "house vacuum" and dissolved in 3 ml of TE buffer (10 mM Tris/HCl, 1 mM EDTA, pH 7.5). The purity of the DNA was determined spectroscopically by forming the ratio of 260 nm to 280 nm as 2.2.

40

The plasmid DNA was isolated from *E. coli* using the QIAprep spin miniprep kit, which is based on alkaline lysis of the cells, exactly in accordance with the manufacturer's (Qiagen) information.

45

19

2. Polymerase chain reaction (PCR)

a) PCR for isolating the P450 BM-3 gene from genomic *Bacillus megaterium* DNA

5

Standard PCR protocol

Repetitions of the program step	Denaturation	DNA annealing	Elongation/DNA-synthesis
Once	95°C, 7 min		
30 times	95°C, 1.5 min	50°C, 1.5 min	72°C, 2 min
Once			72°C, 7 min

10 Standard mixture

15

8 µl of dNTP mix (200µM), 10 µl of Taq polymerase buffer (10 x) without MgCl₂, 8 µl of MgCl₂ (25mM), 1 µl of primer B1 (0.1 µM), 1 µl of primer B2 (0.1 µM), 1 µl of genomic *Bacillus megaterium* DNA, 2.5 U of Taq polymerase (MBI Fermentas, Vilnius, Lithuania), ad 100 µl demineralized water.

20 b) Introduction of tag sequences at the C terminus

25 In order to simplify protein purification and make directed immobilization of P450 BM-3 possible, a C-terminal tag which was six amino acids long in each case was attached to the P450 BM-3 gene. Genomic *Bacillus megaterium* DNA acted as template. The protruding restriction ends chosen for the His, Arg and Glu tags were BamHI and EcoRI in order subsequently to clone the modified 30 P450-BM-3 gene into the plasmid pCYTEXP1. BsaI was chosen for the 5' and 3' ends for the Strep tag; this makes cloning into the plasmid pASK-IBA1CA possible. BsaI cuts only after the 35 recognition sequence, resulting in the protruding restriction ends having a different sequence and thus permitting directed ligation.

40 The standard PCR program and the standard mixture were used for the PCRs. The differences from the standard mixture used for the His₆ tag were the primers H1 and H2, for the Arg₆ tag were the primers A1 and A2, for the Glu₆ tag were the primers G1 and G2 and for the Strep tag the primers S1 and S2.

45 3. Restriction cleavage, electrophoretic separation and purification of DNA fragments

20

DNA is cut sequence-specifically by restriction endonucleases. Restriction cleavage of DNA took place in a reaction volume of 10 μ l in the presence of 2-3 μ l DNA (spin-prep (Qiagen)), 1-2 U of restriction enzyme, 1 μ l of restriction buffer (10x) and ad 5 10 μ l ddH₂O by incubation of the reaction solution at 37°C (apart from BsaI) for two hours in accordance with the manufacturer's method. The DNA fragments were purified by agarose gel electrophoresis in accordance with the method of Sambrook et al. 1989. 0.8-2% agarose gels were used depending on the size of the 10 DNA fragments to be fractionated. TAE buffer (40 mM Tris/HCl, 20 mM acetic acid, 2 mM EDTA, pH 8.3) was used as electrophoresis buffer. Because of the heat evolved, a voltage of 120 V was applied for gels with an agarose concentration of up to 1% and of 100 V for gels with an agarose concentration of up to 2%. 15 Intercalating ethidium bromide (final concentration 0.25 μ M) was used for visualizing the DNA in the transmitted UV light of a transilluminator (312 nm).

DNA fragments were isolated from agarose gels using the QIAquick 20 gel extraction kit (Qiagen). This entails the DNA being immobilized by binding to a silica gel-containing column, and impurities being removed by various washing steps. Up to 8 μ g of DNA (100 bp-10 kb) can be obtained by subsequent elution with demineralized water with this method.

25

4. Ligation and transformation into E. coli

The T4 DNA ligase (New England Biolabs, Beverly, USA) which catalyzes the formation of phosphodiester linkages between 30 5'-phosphate and 3'-hydroxy ends of the DNA, and thus connects two linear DNA molecules or makes the cyclization of a linear molecule possible, was used for ligating DNA.

For the ligation, agarose gel-purified vector and insert 35 fragments (compare section 3.) in the molar ratio of from 1:3 to 1:5 in favor of the insert were placed in an Eppendorf reaction vessel. Before addition of 2 μ l of ligase buffer (10x) and 2-10 U of T4 DNA ligase, demineralized water was added (total volume 20 μ l). The reaction mixtures were incubated at room temperature 40 for one hour or at 7°C overnight.

To prepare competent cells for the transformation, 500 μ l of an E. coli overnight culture were used to inoculate a 250 ml shaken flask containing 50 ml of LB medium. The culture is incubated at 45 37°C and 220 rpm until an OD₆₀₀ of 0.4 - 0.6 is reached after about three hours and is then centrifuged at 5500 g and 4°C for 3 minutes. The cell pellet is resuspended in 2 ml of TSS buffer

21

(10 g PEG6000, 5 ml DMSO, 0.6 g MgSO₄, ad 100 ml LB), incubated on ice and divided into 200 μ l aliquots and, after shock-freezing in liquid nitrogen, stored at -80°C.

5 For the transformation, 5 to 15 μ l of the ligation mixture were added to 200 μ l of the competent cells. After incubation on ice for 30 minutes, the transformation mixture is incubated in a Thermomixer at 42°C for 30 s, and 800 μ l of LB medium at 37°C are added. The mixtures are shaken in an incubator at 37°C for one 10 hour. The cells were then centrifuged at 5500 g (3 minutes), taken up in the drop of LB medium running back, and plated out on LB-Amp agar plates. The agar plates were incubated in an incubator at 37°C overnight.

15 5. DNA sequencing

The DNA sequencing was carried out using the Applied Biosystems DNA 373A automatic sequencer and the dye terminator cycle sequencing kit with AmpliTaq DNA polymerase. The Sanger dideoxy 20 method is used for the sequencing, but dNTPs with fluorescence labels which are incorporated into the synthesized DNA fragments during the sequencing reaction are employed in place of radiolabeled dNTPs.

25 The reaction products were then precipitated with 100 percent ethanol cooled to -20°C. Drying of the DNA and taking up in 4 μ l of a 5:1 mixture of formamide and 25 mM EDTA, pH 8.0, were followed by denaturation of each PCR mixture at 95°C for 5 minutes and immediate transfer of the samples to ice.

30

The DNA fragments labeled with fluorescent dyes pass through a laser beam during the gel electrophoresis. The fluorescent light emitted perpendicular to this beam is measured by photodiodes behind the gel and converted by the software into a graph.

35

Sequencing mixture

8 μ l terminator ready reaction mix; 3.2 pmol of primer;
300-500 ng of template DNA;

40 H₂O ad 20 μ l.

PCR program

Repetitions of the program step	Denaturation	DNA annealing	Elongation/DNA-synthesis
Once	96°C, 6 min		
25 times	96°C, 40 s	50°C, 30 s	60°C, 4 min
Once			60°C, 4 min

10 Composition of sequencing gel:
Urea 30 g (Roth); Rotiphorese NF 10x TBE buffer 6 ml (Roth); acrylamide/bis solution 40% (29:1) 9 ml (Roth); ddH₂O demineralized 23.5 ml.

15 The completed solution is filtered and degassed. The polymerization is started by adding 24 µl of TEMED and 180 µl of 10% (m/v) APS. For details of this, of the analysis of the sequence data and of the dNTP labels, reference may be made to the handbook for the automatic sequencer.

20

6. F87A point mutation using QuikChange kit (Stratagene)

25 To increase the sensitivity of the pNCA assay system, the amino acid phenylalanine at position 87 was replaced by an alanine. In order to be able to identify the point mutant more easily, an additional EaeI restriction cleavage site including the mutation position was introduced, without any other change in the amino acid sequence.

30 In contrast to the standard PCR program, in this case only a four-minute DNA denaturation was carried out, and the sequencing reaction step was carried out at an annealing temperature of 52.3°C, and the 17-minute elongation step was run through only 16 times. The third program was omitted.

35

PCR mixture:

40 1.2 µl of dNTP mix (200 µM), 5 µl of Pfu polymerase buffer (10x), 2.5 U of Pfu polymerase, 2.5 µl of primer F87A1 (5nM), 2.5 µl of primer F87A2 (5nM), 1 µl of pT-USC1BM3 (from mini-preparation diluted 1:20 with demineralized water), ad 50 µl demineralized water.

45 The "annealing" temperature of 52.3°C showed after the above PCR a sharp band with the expected fragment size on a one percent agarose gel.

23

After removal of the mineral oil from the reaction mixture, 1 μ l of *Dpn*I (10 U/ μ l) was added to the PCR mixture and the solution was cautiously mixed by pipetting up and down. It was briefly centrifuged and incubated at 37°C for one hour. During the 5 digestion, the ultracompetent *E. coli* XL1-Blue were thawed on ice and distributed in 50 μ l aliquots in 15 ml Falcon tubes. Addition of 1 μ l of β -mercaptoethanol and 4 μ l of the digested PCR mixture and incubated on ice for 30 minutes were followed by a heat shock at 42°C for 30 s and cooling on ice for two minutes. 450 μ l of 10 warmed (oil bath temperature 42°C) NZY medium (12 g of NZamine, 5 g of yeast extract, 5 g of NaCl, pH 7.5) were added to the transformation mixture. After incubation at 37°C and 220 rpm for one hour and centrifugation (5500 g, 3 min), the cell pellet was resuspended in the remaining liquid and streaked onto LB-Amp 15 plates.

Reference Example 4: Preparative methods

1. Cell disruption

20 Cell pellets with a wet biomass of up to 15 g of *E. coli* DH5 α /pT-USC1BM-3 or DH5 α /pT-USC1BM-3F87A were thawed on ice and suspended in 25 ml of potassium phosphate buffer (50 mM, pH 7.5, 1 mM EDTA) or Tris/HCl buffer (50 mM, pH 7.5, 1 mM EDTA). The 25 ice-cooled *E. coli* cell suspension was disrupted by treatment with ultrasound (Branson Sonifier W250, (Dietzenbach, Germany), power output 80 W, working interval 20%) for three minutes. Before the protein purification, the cell suspension was centrifuged at 32,500 g for 20 min and filtered through a 0.22 μ m 30 Sterivex GP filter (Millipore). This clear solution is referred to as crude extract below.

2. Chromatographic purification of P450 BM-3 using anion exchangers

35 An ÄKTAexplorer system (Amersham Pharmacia Biotech) with a personal computer-based OS/2-UNICORN control software v2.1 and a Frac-900 fraktion collector which permits simultaneous measurement of the total protein elution at 280 nm and P450 BM-3 40 elution at 417 nm was used for the protein purification.

All the analytical P450 BM-3 protein purifications by anion exchange chromatography were carried out at 200 cm/h, at room temperature and with a loading of 6-10 mg of P450 BM-3 per 100 ml 45 of matrix. All the chromatography materials were purchased from TosoHaas (Stuttgart, Germany).

a) Packing and characterization of the chromatography columns

A P450 BM-3 purification protocol was developed by using MPD-DEAE 650S (7.5 mm x 85 mm, particle diameter 35 μ m, Af=1.1, 4100 Tp/m) 5 chromatography columns and XK16/20 (16 mm x 100 mm, APB) chromatography columns packed by us and containing Toyopearl DEAE 650M (Af= 1.1, 1610 Tp/m), SuperQ 650M, (Af= 1.2, 1840 Tp/m) and QAE 550M (Af= 1.0, 1780 Tp/m) with a particle diameter of 65 μ m. An INDEX200 (APB) glass column (20 cm x 19 cm, Af= 1.4, 10 3800 Tp/m), six liters of Toyopearl DEAE 650M and a gear pump (ISMATEC, PB, USA) were used for the preparative chromatographic purifications. In contrast to the analytical P450 BM-3 chromatographic purifications, the ÄKTAexplorer system was used with a 1/20-divided flow as monitor, and the buffers were 15 prepared manually before the preparative purifications. The buffers consisted of Tris/HCl (0.1 M, pH 7.8) with 1 mM EDTA plus 150 mM NaCl for the first, 250 mM NaCl for the second and 1 M NaCl for the third salt stage.

20 b) Choice of the pH, elution and buffer conditions

Preliminary investigations based on active measurements via NADPH consumption showed a suitable pH range between 6.8 and 8.0 for P450 BM-3 purification. Later investigations on the pH stability 25 using the pNCA detection system confirmed this pH range. Anion exchange chromatography with linear NaCl gradients showed that a Tris/HCl buffer (0.1 M, pH 7.8) with 1 mM EDTA is distinctly superior to a phosphate buffer (0.1 M, pH 7.0 to pH 7.5) with 1 mM EDTA in relation to binding capacity and 30 resolving ability for P450 BM-3. For these reasons, the Tris/HCl buffer system was used for all further purification optimizations.

3. Immobilization of the mutant P450 BM-3 F87A

35

a) Preliminary experiments on the selection of the carrier materials

Various adsorptive and covalent methods were investigated in 40 preliminary experiments on the immobilization of P450 BM-3 F87A. 100 mg of carrier material (exception: EP-100, 50 mg) and 5 nmol of P450 BM-3 F87A (from crude extract) were used for all the preliminary experiments.

45 To select a suitable carrier material, for the adsorptive methods 5 nmol of P450 BM-3 F87A were added to the K_3PO_4 buffer (20 mM, pH 7.5, ad 1600 μ l) carrier material suspension in a 2 ml

Eppendorf reacion vessel. The reaction vessels were attached by means of adhesive tape to the outside of a 250 ml round-bottom flask and then subjected to slow inverting rotation on a rotary evaporator for one hour for protein immobilization. To determine 5 the adsorption capacities, the immobilisates were centrifuged at 9000 g for one minute, and 200 μ l of the supernatant were removed for activity measurement.

b) Optimized immobilization procedure for DEAE 650M and Super 10 Q650M

Up to 81 nmol of a P450 BM-3 F87A crude extract or lyophilisate can be immobilized per ml of sedimented DEAE 650M adsorbent material in 5 ml of Tris/HCl buffer (pH 7.5). With the SuperQ 15 650M adsorbent material it is up to 102 nmol of a P450 BM-3 F87A crude extract. For the immobilization, the lyophilisate was taken up in 4 ml of dH₂O in a 15 ml Falcon reaction vessel, and 12-pNCA was added to a final concentration of 0.1 mM. After incubation at room temperature for five minutes, 1 ml of the adsorption matrix, 20 which had been washed twice with 5 ml of water and centrifuged (9000 g, 1 min), was subjected to inverting rotation for half an hour in analogy to the Eppendorf reaction vessels described in the previous section. After centrifugations and removal of the supernatant, the immobilisate was mixed with 5 ml of Tris/HCl 25 buffer (pH 7.5, 0.02 mM), cautiously resuspended and centrifuged again (9000 g, 1 min). This washing process was repeated twice. Tris/HCl buffer (0.1 M, pH 7.5) was added to the immobilisate to a final volume of 2.0 ml, and the latter was resuspended and distributed in 200 μ l aliquots in 1.5 ml Eppendorf reaction 30 vessels which already contained 495 μ l of this buffer. After addition of 5 μ l of 12-pNCA (15 mM) and incubation for five minutes, the reaction was started in an Eppendorf shaker (Ika-Vibrax, with Janke and Kunkel VX2E attachment) by adding 100 μ l of NADPH (1 mM) and was stopped after varying reaction 35 times with 100 μ l of 6 M KOH. After centrifugation at 9000 g (1 min), the supernatant was removed and the absorption at 410 nm was determined.

For the covalent immobilization of P450 BM-3 F87A using 40 glutaraldehyde, P450 BM-3 F87A was disrupted in a 20 mM potassium phosphate buffer (pH 7.5). 5 g of amino-modified Trisopor glasses (Schueller, diameter 500-800 μ m) were exposed to glutaraldehyde vapour in a closed apparatus at room temperature for between three and twelve hours. The amino-modified glasses with 45 glutaraldehyde showed a reddish violet color which was retained even after washing twice with 100 ml of potassium carbonate solution (50 mM, pH 7.8) on a frit. From 50 to 150 mg of these

26

reddish violet glasses were mixed with 0.5-0.8 nmol of P450 BM-3 F87A and shaken in 2 ml Eppendorf reaction vessels in a Retsch ball mill at the lowest setting and 6°C for one hour until the solution was decolorized.

5

4. Enzyme membrane reactor

To check the enzyme membrane reactor concept, 25 nmol of P450 BM-3 F87A were immobilized on 4 ml of SuperQ 650M and added to 10 200 ml of Tris/HCl buffer (pH 7.8) in the reactor reaction vessel. After addition of 1.2 μ mol of 12-pNCA at a flow rate of 40 ml/min the solution was mixed for 20 minutes without counterpressure on the filtration module. With a counterpressure of 2 psi, the reaction was started by addition of 2 ml of aqueous 15 NADPH solution (1 mM) and the course of the reaction was followed by determination at a wavelength of 410 nm. During the course of the reaction, NADPH solution was added in 1 ml steps until 20 conversion of 12-pNCA was complete.

20 Reference Example 5: Chemical syntheses

All ^1H -NMR spectra were recorded with a 500 MHz NMR apparatus, and all ^{13}C -NMR were recorded with a 125 MHz NMR apparatus and CDCl_3 as solvent.


25

1. Preparation of ω -phenoxy carboxylic acids (PCA)

Reaction scheme A points to direct PCA synthesis from ω -bromo carboxylic acids.

30

Reaction scheme A



40

Mixtures

1.01 g	(3.77 mmol)	of bromoundecanoic acid or
1.05 g	(3.77 mmol)	of bromododecanoic acid
45 355 mg	(3.77 mmol)	of phenol
417 mg	(7.44 mmol)	of potassium hydroxide

27

50 ml

of DMF

General reaction procedure

5 Phenol and potassium hydroxide are added to the bromo-fatty acid dissolved in DMF. The solution was heated under reflux at 160°C for 6-7 hours, and the reaction was followed by thin-layer chromatography (TLC, mobile phase petroleum ether : diethyl ether 1:1). After removal of the solvent, the brown precipitate was 10 dissolved in a water-diethyl ether two-phase system (1:1), and dilute hydrochloric acid was used to adjust to a pH of 2. After extraction of the aqueous phase with diethyl ether, the solvent was removed from the combined diethyl ether fractions in a rotary evaporator, the residue was taken up in petroleum ether : ethyl 15 acetate 1:1 and purified using a DC60 silica gel chromatography column (Merck) and the same solvent mixture.

Characterization:

20 ω -Phenoxydodecanoic acid (12-PCA): yield: 76%; m_p := 98-99°C
calculated: C 73.93% H 9.65% O 16.41%, found: C 73.92% H 9.67%

1H-NMR: δ := 7.26-7.29 (m, 2H, phenyl-), 6.88-6.94 (m, 3H, phenyl),
3.94 (t, 2H, phenyl-O-CH₂-, J = 6.5 Hz), 2.35 (t, 2H, -CH₂-COO,
25 J = 7.5 Hz), 1.74-1.80 (m, 2H, -O-CH₂-CH₂-), 1.59-1.66 (m, 2H,
-CH₂-CH₂-COO), 1.42-1.48 (m, 2H, -O-CH₂-CH₂-CH₂-), 1.29-1.35 (m,
12 H, -O-CH₂-CH₂-(CH₂)₆-CH₂-).

13C-NMR: δ := 180.4 (-COO), 159.3 (C 1'), 129.8 (C 3'), 120.8
30 (C 4'), 114.7 (C 2'), 68.3 (-O-CH₂-), 34.5 (-CH₂-COO-), 29.9,
29.8, 29.7, 29.7, 29.5, 29.4, 29.1, 26.5, 25.1 (C-3-C-11).

ω -Phenoxyundecanoic acid (11-PCA): yield: 78%; m_p := 95°C,
calculated: C 73.35% H 9.41% O 17.24%, found: C 73.32% H 9.44%


35 1H-NMR: δ := 7.18-7.21 (m, 2H, phenyl-), 6.81-6.86 (m, 3H, phenyl),
3.87 (t, 2H, phenyl-O-CH₂-, J = 6.5 Hz), 2.27 (t, 2H, -CH₂-COO,
J = 7.5 Hz), 1.67-1.73 (m, 2H, -O-CH₂-CH₂-), 1.53-1.57 (m, 2H,
-CH₂-CH₂-COO), 1.35-1.39 (m, 2H, -O-CH₂-CH₂-CH₂-), 1.18-1.30 (m,
40 10H, -O-CH₂-CH₂-CH₂-(CH₂)₅-CH₂-).

13C-NMR: δ := 180.5 (-COO), 159.5 (C 1'), 129.8 (C 3'), 120.7
(C 4'), 114.7 (C 2'), 68.2 (-O-CH₂-), 34.5 (-CH₂-COO-), 29.9,
29.7, 29.7, 29.7, 29.6, 29.4, 26.4, 25.0 (C-3-C-10).

45

2. Preparation of *p*-nitrophenoxy carboxylic acids (pNCA)

In contrast to the PCA syntheses, a corresponding synthesis of the pNCA compounds was not possible. pNCA synthesis was possible 5 only after esterification of the ω -bromo carboxylic acids and anhydrous conditions were used.



Esterification of ω -bromo carboxylic acids in hexane in accordance with a standard method (Becker et al. 1993) using 35 anhydrous methanol or ethanol solution containing 1 M HCl afforded ω -bromo carboxylic acid methyl esters and ω -bromo carboxylic acid ethyl esters. The course of the reaction was followed by TLC (mobile phase hexane : diethyl ether : acetic acid 70:30:1). The aqueous phase is extracted twice with diethyl 40 ether, and the organic phase is washed twice with saturated sodium bicarbonate solution and once with demineralized water, dried with anhydrous sodium sulfate overnight, filtered and purified by chromatography using petroleum ether : diethyl ether in the ratio 70:30 as mobile phase. After the solvent had been 45 evaporated off in a rotary evaporator, the esters were connected to high vacuum for one hour. In order to prepare the pNCA esters, a small excess of 18.5 nmol of *p*-nitrophenol was added to 17 mmol

29

of ω -bromo carboxylic ester dissolved in 100 ml of DMSO. The solution was heated at 120°C under a reflux condenser for two to three hours. After the pale brownish solution had been cooled to room temperature, demineralized water was added dropwise in order 5 to precipitate the pNCA esters. The precipitate was filtered, washed with 1.5 liters of ice-cold water to remove excess p-nitrophenol and recrystallized in DMSO to give a white powder. To hydrolyze the pNCA esters, a lipase mixture consisting of 100 mg of *Pseudomonas cepacia* (PCL) and 100 mg of *Candida 10 antarctica* lipase B from Amano (Nagoya, Japan) was added to 100 ml of an acetone/water mixture (pH 7.5, 0.2 M potassium phosphate, up to 50% acetone). After addition of the pNCA esters (5 mmol), the suspension was stirred at room temperature for up to 16 h. To remove the immobilized lipase, the clear suspension 15 was filtered and the pNCAs were crystallized by evaporation of acetone. The pNCA compounds were washed with cold water, recrystallized in DMSO and purified by chromatography on silica gel DC60 (Merck, Darmstadt) (petroleum ether : ethyl acetate 1:1 to 1:3).

20

Characterization of the pNCAs

The stated yields of the pNCA are always based on the corresponding pNCA esters as precursors, and the yields of the 25 pNCA esters are always based on the relevant ω -bromo carboxylic acids.

p-Nitrophenoxyhexanoic acid (6-pNCA): yield: 81%; m_p := 94°C

30 $^1\text{H-NMR}$: δ := 8.18 (d, 2H, NO_2 -phenyl-, J = 9.3 Hz), 6.94 (d, 2H, phenyl-O-, J = 9.3 Hz), 4.06 (t, 2H, phenyl-O- CH_2 -, J = 6.3 Hz), 2.42 (t, 2H, $-\text{CH}_2$ -COO, J = 7.1 Hz), 1.80-1.92 (m, 2H, $-\text{O-CH}_2\text{-CH}_2$ -), 1.68-1.77 (m, 2H, $-\text{CH}_2\text{-CH}_2$ -COO), 1.49-1.61 (m, 2H, $-\text{O-CH}_2\text{-CH}_2$ -).

35 $^{13}\text{C-NMR}$: δ := 180.0 (-COOH), 164.1 (C-4'), 141.4 (C-1'), 125.9 (C-2'), 114.4 (C-3'), 68.5 (-O- CH_2 -), 33.9 (- CH_2 -COOH), 28.6, 25.5, 24.3 (C-3, C-5, C-4).

Ethyl *p*-nitrophenoxyhexanoate (6-pNCAEt): yield: 81%

40

$^1\text{H-NMR}$: δ := 8.09 (d, 2H, NO_2 -phenyl-, J = 9.3 Hz), 6.85 (d, 2H, phenyl-O-, J = 9.3 Hz), 4.05 (q, 2H, -COO- CH_2), 3.97 (t, 2H, phenyl-O- CH_2 -, J = 6.4 Hz), 2.26 (t, 2H, $-\text{CH}_2$ -COO, J = 7.3 Hz), 1.69-1.82 (m, 2H, $-\text{O-CH}_2\text{-CH}_2$ -), 1.57-1.67 (m, 2H, $-\text{CH}_2\text{-CH}_2$ -COO), 45 1.40-1.50 (m, 2H, $-\text{O-CH}_2\text{-CH}_2$ -), 1.17 (t, 3H, -COO $\text{CH}_2\text{-CH}_3$).

30

$^{13}\text{C-NMR}$: δ := 173.7 (-COO), 164.3 (C 4'), 141.5 (C 1'), 126.0 (C 2'), 114.6 (C 3'), 68.7 (-O-CH₂-), 60.4 (-COO-CH₂-), 34.3 (-CH₂-COO-), 28.8, 25.7, 24.8 (C-3, C-5, C-4), 14.4 (-O-CH₂-CH₃).

5 *p*-Nitrophenoxyoctanoic acid (8-pNCA): yield: 92%; m_p := 98°C

$^1\text{H-NMR}$: δ := 8.11 (d, 2H, NO₂-phenyl-, J = 9.2 Hz), 6.86 (d, 2H, phenyl-O-, J = 9.3 Hz), 3.97 (t, 2H, phenyl-O-CH₂-, J = 6.4 Hz), 2.29 (t, 2H, -CH₂-COO, J = 7.4 Hz), 1.69-1.80 (m, 2H, -O-CH₂-CH₂), 10 1.56-1.61 (m, 2H, -CH₂-CH₂-COO), 1.32-1.43 (m, 6H, -O-CH₂-CH₂-(CH₂)₃-CH₂-).

$^{13}\text{C-NMR}$: δ := 180.2 (-COOH), 164.3 (C 4'), 141.4 (C 1'), 125.9 (C 2'), 114.4 (C 3'), 68.8 (-O-CH₂-), 34.0 (-CH₂-COOH), 28.9, 15 28.9, 25.8, 24.6 (C-3-C-7).

Methyl *p*-nitrophenoxyoctanate (8-pNCAMe): yield: 79%

$^1\text{H-NMR}$: δ := 8.10 (d, 2H, NO₂-phenyl-, J = 9.2 Hz), 6.86 (d, 2H, phenyl-O-, J = 9.3 Hz), 3.97 (t, 2H, phenyl-O-CH₂-, J = 6.5 Hz), 20 3.59 (s, 3H, -COOCH₃), 2.24 (t, 2H, -CH₂-COO, J = 7.4 Hz), 1.69-1.77 (m, 2H, -O-CH₂-CH₂-), 1.51-1.59 (m, 2H, -CH₂-CH₂-COO), 1.27-1.43 (m, 6H, -O-(CH₂)₂-(CH₂)₃-).

25 $^{13}\text{C-NMR}$: δ := 174.2 (-COO), 164.3 (C 4'), 141.4 (C 1'), 125.9 (C 2'), 114.4 (C 3'), 68.8 (-O-CH₂-), 51.5 (-COO-CH₃), 34.0 (-CH₂-COO-), 29.0, 28.9, 25.8, 24.9 (C-3-C-7).

p-Nitrophenoxydecanoic acid (10-pNCA): yield: 84%; m_p := 101°C

30

$^1\text{H-NMR}$: δ := 8.18 (d, 2H, NO₂-phenyl-, J = 9.2 Hz), 6.93 (d, 2H, phenyl-O-, J = 9.3 Hz), 4.03 (t, 2H, phenyl-O-CH₂-, J = 6.5 Hz), 2.35 (t, 2H, -CH₂-COO, J = 7.4 Hz), 1.75-1.86 (m, 2H, -O-CH₂-CH₂-), 1.60-1.63 (m, 2H, -CH₂-CH₂-COO), 1.32-1.45 (m, 10H, 35 -O-CH₂-CH₂-(CH₂)₅-CH₂-).

$^{13}\text{C-NMR}$: δ := 180.4 (-COO), 164.4 (C 4'), 141.5 (C 1'), 126.1 (C 2'), 114.6 (C 3'), 69.1 (-O-CH₂-), 34.2 (-CH₂-COOH), 29.9, 29.4, 29.4, 29.3, 29.2, 26.3, 26.1, 24.8 (C-3-C-9).

40

Methyl *p*-nitrophenoxydecanoate (10-pNCAMe): yield: 73%

$^1\text{H-NMR}$: δ := 8.11 (d, 2H, NO₂-phenyl-, J = 9.2 Hz), 6.86 (d, 2H, phenyl-O-, J = 9.3 Hz), 3.97 (t, 2H, phenyl-O-CH₂-, J = 6.5 Hz), 45 3.59 (s, 3H, -COOCH₃), 2.23 (t, 2H, -CH₂-COO, J = 7.5 Hz),

31

1.68-1.77 (m, 2H, -O-CH₂-CH₂-), 1.52-1.57 (m, 2H, -CH₂-CH₂-COO), 1.22-1.45 (m, 10H, -O-CH₂-CH₂-(CH₂)₅-CH₂-).

¹³C-NMR: δ:= 174.2 (-COO), 164.2 (C 4'), 141.2 (C 1'), 125.8 (C 2'), 114.3 (C 3'), 68.8 (-O-CH₂-), 51.3 (-COOCH₃), 34.3 (-CH₂-COO-), 29.2, 29.1, 29.1, 29.0, 28.9, 25.8, 24.8 (C-3-C-9).

p-Nitrophenoxyundecanoic acid (11-pNCA): yield: 89%; m_p:= 102°C

10 ¹H-NMR: δ:= 8.19 (d, 2H, NO₂-phenyl-, J=9.2 Hz), 6.94 (d, 2H, phenyl-O-, J= 9.1 Hz), 4.05 (t, 2H, phenyl-O-CH₂-, J= 6.5 Hz), 2.35 (t, 2H, -CH₂-COO, J= 7.6 Hz), 1.79-1.84 (m, 2H, -O-CH₂-CH₂-), 1.61-1.66 (m, 2H, -CH₂-CH₂-COO), 1.43-1.49 (m, 2H, -O-CH₂-CH₂-CH₂-), 1.32-1.45 (m, 10H, -O-CH₂-CH₂-(CH₂)₅-CH₂-).

15

¹³C-NMR: δ:= 180.12 (-COO), 164.3 (C 4'), 141.3 (C 1'), 125.9 (C 2'), 114.4 (C 3'), 68.9 (-O-CH₂-), 34.0 (-CH₂-COO-), 29.4, 29.3, 29.3, 29.2, 29.0, 29.0, 25.9, 24.6 (C-3-C-10).

20 Methyl *p*-nitrophenoxyundecanoate (11-pNCAMe): yield: 80%

¹H-NMR: δ:= 8.18 (d, 2H, NO₂-phenyl-, J=9.3 Hz), 6.93 (d, 2H, phenyl-O-, J= 9.2 Hz), 4.03 (t, 2H, phenyl-O-CH₂-, J= 6.5 Hz), 3.66 (s, 3H, -COOCH₃), 2.29 (t, 2H, -CH₂-COO, J= 7.5 Hz),

25 1.75-1.86 (m, 2H, -O-CH₂-CH₂-), 1.58-1.64 (m, 2H, -CH₂-CH₂-COO), 1.29-1.45 (m, 12H, -O-CH₂-CH₂-(CH₂)₆-CH₂-).

¹³C-NMR: δ:= 174.5 (-COO), 164.4 (C 4'), 141.5 (C 1'), 126.1 (C 2'), 114.6 (C 3'), 69.0 (-O-CH₂-), 51.6 (-COOCH₃), 34.2

30 (-CH₂-COO-), 29.6, 29.5, 29.4, 29.4, 29.3, 29.1, 26.1, 25.1 (C-3-C-10).

p-Nitrophenoxydodecanoic acid (12-pNCA): yield: 89%; m_p:= 106°C

35 calculated: C 64.07% H 8.07% N 4.06%, O 23.71%, found: C 63.99% H 8.18% N 4.15%

¹H-NMR: δ:= 8.19 (d, 2H, NO₂-phenyl-, J=9.3 Hz), 6.94 (d, 2H, phenyl-O-, J= 9.4 Hz), 4.04 (t, 2H, phenyl-O-CH₂-, J= 6.6 Hz), 40 2.35 (t, 2H, -CH₂-COO, J= 7.5 Hz), 1.79-1.84 (m, 2H, -O-CH₂-CH₂-), 1.60-1.66 (m, 2H, -CH₂-CH₂-COO), 1.43-1.49 (m, 2H, -O-CH₂-CH₂-CH₂-), 1.29-1.35 (m, 12H, -O-CH₂-CH₂-(CH₂)₆-CH₂-).

¹³C-NMR: δ:= 180.4 (-COO), 164.3 (C 4'), 141.3 (C 1'), 125.9 (C 2'), 114.4 (C 3'), 68.9 (-O-CH₂-), 34.1 (-CH₂-COO-), 29.5, 29.4, 29.3, 29.2, 29.2, 29.0, 29.0, 25.9, 24.7 (C-3-C-11).

32

Ethyl *p*-nitrophenoxydodecanoate (12-*p*NCAEt): yield: 73%

¹H-NMR: δ = 8.18 (d, 2H, NO_2 -phenyl-, $J=9.2$ Hz), 6.94 (d, 2H, phenyl-O-, $J=9.3$ Hz), 4.12 (q, 2H, $-\text{COO-CH}_2-$, $J=7.1$ Hz) 4.05 (t, 5 2H, phenyl-O- CH_2- , $J=6.5$ Hz), 2.29 (t, 2H, $-\text{CH}_2\text{-COO}$, $J=7.5$ Hz), 1.70-1.87 (m, 2H, $-\text{O-CH}_2\text{-CH}_2-$), 1.59-1.69 (m, 2H, $-\text{CH}_2\text{-CH}_2\text{-COO}$), 1.32-1.45 (m, 14H, $-\text{O-CH}_2\text{-CH}_2\text{-(CH}_2)_7\text{-CH}_2-$), 1.26 (t, 3H, $-\text{COOCH}_2\text{-CH}_3$, $J=7.2$ Hz).

10 ¹³C-NMR: δ = 174.8 ($-\text{COO}$), 164.4 (C 4'), 141.5 (C 1'), 126.1 (C 2'), 114.6 (C 3'), 69.0 ($-\text{O-CH}_2-$), 60.5 ($-\text{COO-CH}_2-$), 34.2 ($-\text{CH}_2\text{-COO-}$), 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 26.1, 25.1 (C-3-C-11), 14.4 ($-\text{COO-CH}_2\text{-CH}_3$).

15 *p*-Nitrophenoxypentadecanoic acid (15-*p*NCA): yield: 87%; m_p = 115°C

¹H-NMR: δ = 8.19 (d, 2H, NO_2 -phenyl-, $J=9.2$ Hz), 6.94 (d, 2H, phenyl-O-, $J=9.3$ Hz), 4.05 (t, 2H, phenyl-O- CH_2- , $J=6.5$ Hz), 2.35 (t, 2H, $-\text{CH}_2\text{-COO}$, $J=7.5$ Hz), 1.79-1.85 (m, 2H, $-\text{O-CH}_2\text{-CH}_2-$), 20 1.59-1.66 (m, 2H, $-\text{CH}_2\text{-CH}_2\text{-COO}$), 1.43-1.49 (m, 2H, $-\text{O-CH}_2\text{-CH}_2\text{-CH}_2-$), 1.26-1.35 (m, 18H, $-\text{O-CH}_2\text{-CH}_2\text{-CH}_2\text{-(CH}_2)_9\text{-CH}_2-$).

¹³C-NMR: δ = 180.0 ($-\text{COO}$), 164.3 (C 4'), 141.3 (C 1'), 126.0 (C 2'), 114.4 (C 3'), 68.9 ($-\text{O-CH}_2-$), 34.0 ($-\text{CH}_2\text{-COO-}$), 29.6, 25 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 29.0, 25.9, 24.7 (C-3-C-14).

Methyl *p*-nitrophenoxypentadecanoate (15-*p*NCA*Me*): yield: 75%

30 ¹H-NMR: δ = 8.19 (d, 2H, NO_2 -phenyl-, $J=9.2$ Hz), 6.94 (d, 2H, phenyl-O-, $J=9.3$ Hz), 4.05 (t, 2H, phenyl-O- CH_2- , $J=6.5$ Hz), 3.66 (s, 3H, $-\text{COOCH}_3$), 2.26 (t, 2H, $-\text{CH}_2\text{-COO}$, $J=7.5$ Hz), 1.79-1.85 (m, 2H, $-\text{O-CH}_2\text{-CH}_2-$), 1.59-1.66 (m, 2H, $-\text{CH}_2\text{-CH}_2\text{-COO}$), 1.43-1.49 (m, 2H, $-\text{O-CH}_2\text{-CH}_2\text{-CH}_2-$), 1.26-1.35 (m, 18H, 35 $-\text{O-CH}_2\text{-CH}_2\text{-CH}_2\text{-(CH}_2)_9\text{-CH}_2-$).

¹³C-NMR: δ = 174.6 ($-\text{COO}$), 164.3 (C 4'), 141.3 (C 1'), 126.0 (C 2'), 114.4 (C 3'), 68.9 ($-\text{O-CH}_2-$), 51.7 ($-\text{COOCH}_3$), 34.0 ($-\text{CH}_2\text{-COO-}$), 29.7, 29.6, 29.5, 29.5, 29.4, 29.3, 29.3, 29.2, 29.1, 40 29.1, 26.1, 25.0 (C-3-C-14).


3. Preparation of resorufinyl carboxylic acids (RCA)

a) Preparation of methyl ω -resorufinyl dodecanoate and methyl 45 ω -resorufinyl undecanoate

33

For the RCA synthesis, the ω -bromo carboxylic acids were esterified in accordance with the procedure for the pNCA compounds, reacted with the sodium salt of resorufin in DMF and hydrolyzed using a PCL/CAL-B lipase mixture.

5

Mixture for methyl ω -resorufinylaurate:

25

0.90 g (3.1 mmol) of methyl 12-bromolaurate
 0.72 g (3.1 mmol) of resorufin
 50 ml of DMF

30 Mixture for methyl ω -resorufinylundecanoate:

0.75 g (2.7 mmol) of methyl 11-bromoundecanoate
 0.63 g (2.7 mmol) of resorufin
 50 ml of DMF

35

Procedure:

Resorufin is added to a solution of the bromo-fatty acid ester in DMF but does not completely dissolve. The dark violet suspension 40 is heated under reflux for four hours, and the reaction is followed by TLC (mobile phase petrol ether:diethyl ether 1:1). After removal of the solvent, the brown precipitate is dissolved in petroleum ether:ethyl acetate 1:1 for half an hour and purified using a DC60 (Merck) silica gel chromatography column in 45 the same mobile phase mixture. The chosen column should not be

34

too large because the compound decomposes to a small extent on the column.

Methyl ω -resorufinylaurate: yield: 17%

5

$^1\text{H-NMR}$: δ = 7.62 (d, 1H, -H-9', J = 8.89 Hz), 7.35 (d, 1H, -H-1', J = 9.79 Hz), 6.85 (dd, 1H, -H-8', J_{8',9'} = 8.87 Hz, J_{8',6'} = 2.41 Hz), 6.76 (dd, 1H, -H-2', J_{2',1'} = 9.74 Hz, J_{2',4'} = 1.74 Hz), 6.73 (d, 1H, -H-6', J = 2.40 Hz), 6.25 (d, 1H, -H-4', J = 1.74 Hz), 3.98 (t, 2H, phenyl-O-CH₂-, J = 6.50 Hz), 3.59 (s, 3H, -COO-CH₃), 2.23 (t, 2H, -CH₂-COO, J = 7.50 Hz), 1.73-1.79 (m, 2H, -O-CH₂-CH₂-), 1.53-1.56 (m, 2H, -CH₂-CH₂-COO), 1.37-1.41 (m, 2H, -O-CH₂-CH₂-CH₂-), 1.22-1.29 (m, 12H, -O-CH₂-CH₂-CH₂-(CH₂)₆-CH₂-).

10

$^{13}\text{C-NMR}$: δ = 186.7 (-C 3'), 174.7 (-COO), 163.7, 150.3, 146.1, 145.7 (C 4a', C-5a', C-9a', C-10a'), 135.1, 134.5, 131.9, 128.7, 114.5, 107.1, 100.8 (C 2', C 4', C 1', C 9', C 6', C 8', C 9'), 69.5 (-O-CH₂-), 51.9 (-COO-CH₃), 34.5 (-CH₂-COO-), 30.1, 29.8, 29.7, 29.6, 29.5, 29.3, 26.3, 25.3 (C-3-C-11).

20

Methyl ω -resorufinylundecanoate: yield: 15%;

$^1\text{H-NMR}$: δ = 7.62 (d, 1H, -H-9', J = 8.91 Hz), 7.35 (d, 1H, -H-1', J = 9.70 Hz), 6.86 (dd, 1H, -H-8', J_{8',9'} = 8.90 Hz, J_{8',6'} = 2.53 Hz), 6.76 (dd, 1H, -H-2', J_{2',1'} = 9.72 Hz, J_{2',4'} = 1.95 Hz), 6.73 (d, 1H, -H-6', J = 2.54 Hz), 6.25 (d, 1H, -H-4', J = 1.94 Hz), 3.98 (t, 2H, phenyl-O-CH₂-, J = 6.49 Hz), 3.60 (s, 3H, -COO-CH₃), 2.23 (t, 2H, -CH₂-COO, J = 7.50 Hz), 1.74-1.79 (m, 2H, -O-CH₂-CH₂-), 1.54-1.57 (m, 2H, -CH₂-CH₂-COO), 1.35-1.42 (m, 30 2H, -O-CH₂-CH₂-CH₂-), 1.18-1.29 (m, 10H, -O-CH₂-CH₂-CH₂-(CH₂)₅-CH₂-).

$^{13}\text{C-NMR}$: δ = 186.7 (-C 3'), 174.7 (-COO), 163.7, 150.3, 146.1, 145.7 (C 4a', C-5a', C-9a', C-10a'), 135.0, 135.0, 132.0, 128.6, 35 114.5, 107.0, 100.8 (C 2', C 4', C 1', C 9', C 6', C 8', C 9'), 69.5 (-O-CH₂-), 51.8 (-COO-CH₃), 34.5 (-CH₂-COO-), 29.9, 29.8, 29.7, 29.6, 29.5, 29.3, 26.3, 25.3 (C-3-C-10).


40

45

35

b) Preparation of ω -resorufinyldodecanoic acid and ω -resorufinylundecanoic acid


5



10

0.1 M aqueous phosphate buffer pH 7.3
 Lipase; T = 40°C; n = 5, 6
 10% acetone as solubilizer

15



20

+ MeOH

Preliminary experiments:

Chemical hydrolysis using NaOH led to cleavage of the ester, but 25 isolation of the required yellow-orange product was possible in yields of only 10%; the cause of this is decomposition of the resorufinyl aromatic system in strongly alkaline solutions (pH>12) with loss of color. Five products were detectable on TLC plates. In alkaline medium, the resorufinyl-fatty acid ester 30 shows a greenish color. Cleavage using lipases was considerably more successful after optimization of the workup. To choose a suitable lipase, the following lipases were tested in a 0.1 M sodium phosphate buffer pH 7.5 with 10% acetone as solubilizer at 40°C in a Thermomixer overnight: *Candida antarctica* lipase A and 35 B, *Aspergillus niger* lipase and *Pseudomonas cepacia* lipase (PCL).

The *Candida antarctica* lipase B and the PCL cleave the resorufinyl carboxylic esters, and eventually the PCL was used for the preparative ester cleavage.

40

Mixture for ω -resorufinyldodecanoic acid:

40 mg	(94 μ mol)	of methyl ω -resorufinyldodecanoate
2 ml		of acetone
45 18 ml		sodium phosphate buffer, pH 7.3
spatula tip		of PCL

36

Mixture for ω -resorufinylundecanoic acid:

36 mg (30 μ mol) of methyl ω -resorufinylundecanoate
 2 ml of acetone
 18 ml of sodium phosphate buffer, pH 7.3
 5 spatula tip of PCL

Procedure:

The esters are dissolved in acetone in a 50 ml round-bottom flask
 10 and, after addition of 9 ml of sodium phosphate buffer, pH 7.3, a spatula tip of PCL is added, and the mixture is incubated at 40°C overnight. The course of the reaction is followed by TLC (mobile phase petroleum ether : diethyl ether 1:1). After cautious extraction with chloroform several times, the chloroform phase is
 15 washed twice with demineralized water, dried over sodium sulfate for four hours, filtered and concentrated in a rotary evaporator.

ω -Resorufinylauric acid: yield: 73%

20 $^1\text{H-NMR}$: δ := 7.62 (d, 1H, -H-9', J = 8.9 Hz), 7.35 (d, 1H, -H-1', J = 9.8 Hz), 6.85 (dd, 1H, -H-8', $J_{8',9'} = 8.87$ Hz, $J_{8',6'} = 2.4$ Hz), 6.76 (dd, 1H, -H-2', $J_{2',1'} = 9.7$ Hz, $J_{2',4'} = 1.7$ Hz), 6.73 (d, 1H, -H-6', J = 2.4 Hz), 6.25 (d, 1H, -H-4', J = 1.7 Hz), 3.98 (t, 2H, phenyl-O-CH₂-, J = 6.5 Hz), 2.34 (t, 2H, -CH₂-COO, J = 7.5 Hz),
 25 1.73-1.79 (m, 2H, -O-CH₂-CH₂-), 1.55-1.59 (m, 2H, -CH₂-CH₂-COO), 1.37-1.41 (m, 2H, -O-CH₂-CH₂-CH₂-), 1.22-1.29 (m, 12H, -O-CH₂-CH₂-CH₂-(CH₂)₆-CH₂-).

30 $^{13}\text{C-NMR}$: δ := 186.6 (-C 3'), 180.4 (-COO), 163.7, 150.3, 146.1, 145.7 (C 4a', C-5a', C-9a', C-10a'), 135.1, 134.5, 131.9, 128.7, 114.5, 107.1, 100.8 (C 2', C 4', C 1', C 9', C 6', C 8', C 9'), 69.5 (-O-CH₂-), 34.2 (-CH₂-COO-), 30.1, 29.8, 29.7, 29.7, 29.6, 29.5, 29.3, 26.3, 25.3 (C-3-C-11).

35 ω -Resorufinylundecanoic acid: yield: 78 %

1H-NMR: δ := 7.63 (d, 1H, -H-9', J = 8.9 Hz), 7.35 (d, 1H, -H-1', J = 9.7 Hz), 6.85 (dd, 1H, -H-8', $J_{8',9'} = 8.9$ Hz, $J_{8',6'} = 2.53$ Hz), 6.76 (dd, 1H, -H-2', $J_{2',1'} = 9.7$ Hz, $J_{2',4'} = 1.9$ Hz), 6.73 (d, 1H, -H-6', J = 2.5 Hz), 6.25 (d, 1H, -H-4', J = 1.9 Hz), 3.98 (t, 2H, phenyl-O-CH₂-, J = 6.5 Hz), 2.35 (t, 2H, -CH₂-COO, J = 7.5 Hz), 1.74-1.79 (m, 2H, -O-CH₂-CH₂-), 1.54-1.59 (m, 2H, -CH₂-CH₂-COO), 1.35-1.42 (m, 2H, -O-CH₂-CH₂-CH₂-), 1.18-1.29 (m, 10H, -O-CH₂-CH₂-CH₂-(CH₂)₅-CH₂-).

37

¹³C-NMR: δ:= 186.7 (-C 3'), 180.7 (-COO), 163.7, 150.3, 146.1, 145.7 (C 4a', C-5a', C-9a', C-10a'), 135.0, 135.0, 132.0, 128.6, 114.5, 107.0, 100.8 (C 2', C 4', C 1', C 9', C 6', C 8', C 9'), 69.5 (-O-CH₂-), 34.1 (-CH₂-COO-), 29.9, 29.8, 29.7, 29.6, 29.5, 5 29.3, 26.3, 25.3 (C-3-C-10).

c) Activity test for P450 BM-3 with ω-resorufinyl lauric acid and ω-resorufinyl undecanoic acid:

10 A spatula tip of the 11- or 12-RCA was dissolved in 0.5 ml of acetone, ethanol, THF, dioxane and 5.5 ml of potassium phosphate buffer (pH 7.5, 0.1 M). 5 ml of potassium phosphate buffer (pH 7.5, 0.1 M) were added to the organic solvents acting as solubilizers. Addition of 5 nmol of P450 was followed by 15 incubation at room temperature for 10 minutes, and the P450 BM-3 was reduced by addition of 200 µl of NADPH (50 µM). After one hour, 200 µl of the respective reaction mixtures were transferred into a microtiter plate. Corresponding blank samples without added NADPH are additionally pipetted into the second row.

20

Reference Example 6: Analytical methods

1. Protein separation in SDS polyacrylamide gel electrophoresis (SDS-PAGE)

25

Proteins can be fractionated according to size by SDS-PAGE. Before the gel electrophoresis, purified protein samples were mixed 1:1 with SDS sample buffer (Tris/HCl 500 mM, pH 6.8, glycerol 10% (v/v), SDS 20% (w/v), mercaptoethanol 2% (w/v), 30 bromophenol blue 0.05%) and heated at 95°C for 5 min to denature the protein. For analysis of protein expression in *E. coli* cells, after a five-hour induction phase (OD₅₇₈ = 1.5-2.0) 1 ml of the culture was removed by pipette and centrifuged at 12,000 g. The cell pellet was disrupted with 100 µl of the sample buffer and 35 centrifuged at 12,000 g for 1 min. Cooling the protein samples on ice was followed by protein fractionation in electrophoresis buffer (9.0 g of Tris, 43.2 g of glycerol, 3.0 g of SDS, ddH₂O ad 600 ml) at 25 mA per gel.

40 A low molecular weight marker (phosphorylase B 97.4 kDa, BSA 66.3 kDa, ovalbumin 45.0 kDa, carbonic anhydrase 31.0 kDa, trypsin inhibitor 21.5 kDa, lysozyme 14.4 kDa) and a high molecular weight kit (myosin 200 kDa, β-galactosidase 116.25 kDa, phosphorylase B 97.4 kDa, BSA 66.3 kDa, ovalbumin 45 kDa) from 45 Bio-Rad (Richmond, USA) were used as protein standard.

Used for protein separation was a 7.5 percent resolving gel (2.5 ml of Tris/HCl (1.5 M, pH 8.8), 100 μ l of SDS (10% m/v), 2.5 ml of acrylamide : N,N'-methylenebisacrylamide 30 : 1 (Roth), 50 μ l of APS, 5 μ l of TEMED) and a 4 percent stacking gel (1 ml of 5 stacking gel buffer (12.11 g of Tris, 0.8 g of SDS, ad H₂O 200 ml, pH 6.8 adjusted with HCl), 0.52 μ l of acrylamide : N,N'-methylenebisacrylamide 30:1 (Roth), 40 μ l of APS 10% (w/v), 4 μ l of TEMED. Following the electrophoresis, the fractionated proteins were stained blue with staining solution (0.1% Coomassie 10 Brilliant Blue R250, 10% (v/v) acetic acid, 30% methanol) with slow shaking for three hours. Incubation in destaining solution (10% (v/v) acetic acid, 30% methanol) took place until clear protein bands were visible. For documentation, the gel was placed free of air bubbles between a cellulose filter paper and a 15 copying sheet and dried in a gel dryer (Bio-Rad, Model 583) at 80°C under house vacuum for two hours.

2. Determination of the protein content by detection of BCA

20 Protein concentrations were determined using the bicinchoninic acid (BCA) protein detection system from Pierce (St. Augustin, Germany) by spectrometry at 562 nm in accordance with the standard protocol provided by the manufacturer. Calibration lines were recorded using BSA dilutions.

25

3. Spectroscopic detection methods

All spectroscopic UV-Vis detections were carried out under aerobic conditions in a Pharmacia spectrophotometer, model 30 BioChrom4060 (APB, Uppsala, Sweden), with BioChrom4060 Windows 3.11 Software v2.0.

a) Determination of the P450 concentration

35 P450 BM-3 concentrations were determined using the CO difference spectroscopic method (Omura et al. 1964) and an extinction coefficient of $\epsilon = 91 \text{ mM}^{-1} \cdot \text{cm}^{-1}$ with a chart speed of 125 nm/min at 0.1 nm intervals. For this, a spatula tip of sodium dithionite and 10 μ l of a 0.1 percent (w/v) aqueous methylviologen solution 40 were added to 5 ml of phosphate-buffered (20 mM, pH 7.3 to 7.5) P450 BM-3 crude extract. The sample, which was deep blue to bluish green depending on the P450 BM-3 concentration, was divided into two fractions. One of the two fractions was gassed with CO for one minute, avoiding foam formation, and the other is 45 used as reference for the difference spectroscopic measurement.

b) Measurement of the reductase activity

The measurements were carried out at room temperature in 0.1 M potassium phosphate buffer pH 7.4, measuring the increase in absorption at 550 nm with $\epsilon = 8.9 \text{ mM}^{-1}$ (Fulco et al. 1992). 1 ml of sample contained 50 nmol of cytochrome c (from horse heart), 100 nmol of NADPH and an amount of P450 BM-3 which is evident from Table 6. The same sample before addition of NADPH was used as reference. The solutions were freshly prepared and stored on ice until used the same day. To measure the reductase activity of P450 BM-3His₆, the NADPH solution was added to the cytochrome c solution after incubation for five minutes.

4. Protocols for characterization of P450 BM-3 and/or P450 BM-3 F87A

Purified P450 BM-3 F87A was used to measure the kinetic constants and the pH stability and temperature stability. Centrifuged and filtered clear crude extract was used for all the other determinations. 0.05-0.2 nmol of P450 BM-3 or P450 BM-3 F87A in a total volume of 1 ml and 8 μl of 5-15 mM pNCA solution were used per mixture for all the experiments. Characterization experiments, with the exception of the solvent tests, were carried out in 1 ml disposable plastic cuvettes. Unless described otherwise, the tests were carried out at room temperature.

a) Determination of the kinetic constants

The kinetic constants were measured after addition of 792 μl of Tris/HCl (pH 8.2, 0.2 M) and 100 μl of P450 BM-3 to 8 μl of DMSO substrate solution of varying substrate concentration. After incubation at room temperature for five minutes, the reaction was started by adding 100 μl of 1 mM NADPH solution.

35 b) Solvent stability of P450 BM-3 F87A

The solvent stabilities were measured in glass cuvettes (Hellma, model 6040), dissolving the substrate in acetone, dioxane, THF and ethanol instead of DMSO. The determinations were carried out by the procedure described for the kinetic measurements; however, as a difference from this, the proportion of the buffer was varied according to the amount of solvent used.

40

c) pH stability and temperature stability of P450 BM-3 F87A

The measurement of the pH stability was carried out at 30°C in a Stratagene Robocycler (gradient40 model) in thin-wall 0.5 ml PCR reaction vessels (Stratagene). 392 µl of phosphate-buffered solution (50 mM, pH 4-10) were added to 0.1-0.2 nmol of P450 BM-3. After the incubation period, the P450 BM-3 solution was transferred into a cuvette, and 500 µl of Tris/HCl (0.3 M, pH 8.2) and 8 µl of 12-pNCA (6 mM) were added. After incubation for five minutes, the reaction was started by means of 100 µl of NADPH solution (1 mM). The temperature stability was investigated at a pH of 7.5 under the same conditions as the pH stability.

d) Effect of buffer salt concentrations, detergents, protease inhibitors, thio compounds, Co(III) sepulchrate on the P450 BM-3 F87A activity

The effects of these compounds on the P450 BM-3 F87A activity were investigated in analogy to the kinetic investigations, replacing a varying part of the buffer by the substance for investigation dissolved in the same buffer system.

e) Automated activity detection

25 Microtiter plates with 96 reaction chambers (Greiner Frickenhausen, Germany) were chosen for the automated P450 BM-3 F87A activity detection. The total reaction volume was 250 µl in a Tris/HCl buffer (0.1 M, pH 8.2) with 18 nmol of 10- and 11-pNCA, 12 nmol of 12-pNCA or 10 nmol of 15-pNCA, which were 30 dissolved in 2.2 µl of DMSO. A Biomek2000 robotic pipettor (Beckman Instruments, Fullerton, USA) was used for the pipetting work. After an incubation time of five minutes with 0.02 nmol of P450 BM-3 F87A, the reaction was started by injecting 25 µl of an aqueous NADPH solution (1 mM) into each reaction chamber. The 35 course of the reaction was followed by the absorption at 405 nm in a FluoStar microtiter plate reader (BMG LabTechnology, Offenburg, Germany).

f) Hydrogen peroxide investigations

40

The procedure for activity investigations was as described for the kinetic measurements, except that varying amounts of aqueous hydrogen peroxide were added in place of NADPH.

45 In the stability investigations, 0.05-0.1 nmol of P450 BM-3 F87A was incubated in the absence of pNCA substrate with varying amounts of hydrogen peroxide for five minutes. After addition of

41

catalase (600 U) and a further incubation time of five minutes, 60 nmol of 12-pNCA substrate were pipetted into the reaction solution. The reaction was started five minutes later by adding 100 µl of NADPH (1 mM).

5

g) Zn mediator investigations

The reactions were carried out in an Eppendorf reaction vessel shaker (IKA-Labortechnik Vibrax with Janke and Kunkel type VX2E 10 attachment). The procedure for activity investigations was as described for the kinetic measurements, except that varying amounts of zinc/cobalt(III) sepulchrate were used in place of NADPH. After varying time intervals, 100 µl of sample were removed from the reaction suspension and pipetted into another 15 1.5 ml Eppendorf reaction vessel which contained 10 µl of KOH (6 M) to stop the reaction. After centrifugation at 12,000 g for one minute, the supernatant was removed and the absorption at 410 nm was measured.

20 Example 1: Cloning, expression and purification of P450 BM-3 and mutants on the gram scale

1. Cloning of the P450 BM-3 gene and of the mutant P450 BM-3 F87A and expression thereof in 30 l fermentations

25

The P450 BM-3 gene was isolated by PCR from the genomic DNA from *Bacillus megaterium*, provided with tags and cloned into the expression vectors pCYTEXP1 and pASK-IBA1CA as shown in Figure 1 for the pT plasmids. The sequencing primers R0_5 to L7 were used 30 to check correct insertion of the P450 BM-3 gene, the P450 BM-3 variants provided with different tags and to check the P450 BM-3 F87A point mutant. For the PCRs by the standard protocol, the primers B1 and B2 were used for the wild-type enzyme, the primers H1 and H2 were used for the P450 BM-3His₆, the primers G1 and G2 35 were used for P450 BM-3Glu₆, the primers A1 and A2 were used for P450 BM-3Arg₆, and the primers S1 and S2 were used for 450 BM-3Strep. Sequence analysis revealed no mutations at all for one of in each case three sequenced pT-USC0BM3 and pT-USC1BM3 plasmids. Correct insertion of the tag was checked for pT-USC2BM3 40 and pT-USC3BM3 only with the primer R7. The sequenced pA-USC4BM3 clone showed two mutations in the reductase portion of the P450 BM-3 protein. The expression rate of the P450 BM-3 provided with a His₆ tag in DH5 α was 300 nmol per liter of fermenter broth which was about 20% higher than for the wild type. Because of this 45 higher expression rate, pT-USC1BM3 underwent point mutation by replacing a phenylalanine at position 87 by alanine using the Stragene QuikChange kit to increase the sensitivity of the pNCA

test. The PCR with the primers F87A1 and F87A2 results in pT-USC1BM3F87A containing at the mutation position, without a further alteration in the protein sequence, an additional *EaeI* restriction cleavage site which was used to select the clone 5 selected for the sequencing. This additional restriction cleavage site results, after restriction cleavage with *EaeI*, in the appearance of a new band at about 800 bp in lane 2, and a distinctly smaller band, compared with the wild-type digestion, at 1.7 kbp in lane 1. After plasmid isolation, eight clones were 10 digested with *EaeI* (2 μ l of *EaeI* buffer (10x), 1 μ l of *EaeI*, 3.2 μ l of pT-USC1BM3, ad 20 μ l ddH₂O, 1 h at 37°C). One clone was sequenced. The pT-USC1BM3F87A plasmid has an additional mutation R470C at position 470 in the linker region. No back-mutation was carried out because the R470C mutation was located at the end of 15 the linker region which connects the P450 portion of the P450 BM-3 to the reductase portion and shows no effect at all on the P450 BM-3 activity.

2. Purification of P450 BM-3 and P450 BM-3 F87A

20

The aim was to develop a method for purifying P450 BM-3 and P450 BM-3 F87A which is inexpensive, quick and capable of being carried out on the preparation scale. To this end, an Arg₆, His₆, Glu₆ and Strep tag was attached to the C-terminal end of P450 25 BM-3. It was intended to develop affinity purifications on the basis of the His₆ and Strep tags and chromatographic purifications with ion exchangers on the basis of the Arg₆ and Glu₆ tags. An introduction of one tag at the N-terminal end of the P450 BM-3 gene was not taken into consideration because of the location of 30 the N-terminus is in the region of the flexible substrate entry channel. The modification in this region would very probably lead to an alteration of P450 BM-3 activity and selectivity.

2.1 Protein purifications by affinity chromatography

35

a) P450 BM-3 with His₆ tag

In the purification of P450 BM-3His₆ by metal chelate chromatography, more than 95% of the loaded 4 mg of P450 BM-3 do 40 not bind to the 20 ml XK16/20 affinity column with a linear 0-0.5 molar imidazole gradient (10CV). Chromatographic purification with Zn²⁺ ions was carried out by the standard Pharmacia protocol. The little purified P450 BM-3 no longer showed any activity in the NADPH assay. The cause of this inhibition might be attributed 45 to the effect of imidazole. Imidazole brings about detachment of the fifth cysteinate ligand at the catalytic heme site. This dissociation of the fifth ligand off from the heme system leads

43

to immediate inactivation of P450 and is evident in the CO difference spectrum through a characteristic shift in the absorption maximum from 448 nm to 420 nm.

5 b) P450 BM-3 with Strep tag

8.2 mg of P450 BM-3Strep were used for purification. Comparable with the results for the His₆ tag purifications, P450 BM-3Strep showed no binding to the streptavidin affinity matrix on 10 purification in accordance with the READY TO USE KIT (IBA, Göttingen).

c) P450 BM-3 with Glu₆ tag

15 Comparison of the linear 0-1 M NaCl gradients (12 CV, Tris/HCl buffer (0.1 M, pH 8.0)) showed no differences from the wild-type enzyme in the elution characteristics for P450 BM-3Glu₆ on use of Super 650M and DEAE 650M anion exchangers.

20 d) Conclusions

The results of the purification of P450 BM-3 with His₆, Glu₆ and Strep tags lead to the conclusion that the C-terminal end of P450 BM-3 is not freely accessible on the protein surface and thus 25 cannot be used for purification purposes. In addition, in the case of the His₆ tag, elution with imidazole caused rapid protein inactivation due to displacement of the fifth ligand on the porphyrin system.

30 2.2 Anion exchange chromatography

In order to minimize the costs, it was intended to develop an efficient and time-saving purification method at reasonable cost and allowing simple scale-up for P450 BM-3. Thus, after the 35 results of the purification of P450 BM-3 with tags, the only methods available for P450 BM-3 purification were HIC materials and ion exchangers. The decision was made in favor of anion exchangers which are usually cheaper and simpler to handle.

40 a) Linear and stepped gradient

In order to develop an anion exchange chromatography method, four anion exchange materials of different strengths, DEAE 650S (35 µm), DEAE 650M (65 µm), SuperQ 650M (65 µm) and QAE 550M 45 (65 µm), were investigated for their suitability. In the initial experiments, a linear 0-1 M NaCl gradient 10 column volumes (CV) long was taken up in a Tris/HCl buffer (0.1 M, pH 7.8) with each

44

column material for purifying 6-10 mg of P450 BM-3 crude extract. The yield was 80-84% in all cases. The highest proportions of protein in the P450 BM-3 elution peak were shown by the DEAE material, closely followed by the SuperQ and QAE material.

5

For further improvement of the resolution using stepped salt gradients, the ability of the AKTAexplorer system to record simultaneously the conductivity and absorption at 280 nm and 417 nm was helpful. An optimized two-step salt gradient for the 10 DEAE 650M chromatography column has a first step of 150 mM NaCl and a second with 250 mM NaCl. Elution of P450 BM-3 starts, as is evident from the conductivities of the linear NaCl salt gradient, when the NaCl concentration is increased from 150 mM to 170 mM. The minimum upper salt step was found to be 250 mM NaCl; NaCl 15 concentrations < 230 mM cause broadening of the P450 BM-3 elution peak, and NaCl concentrations > 300 mM result in a distinctly less good purification effect. The salt steps were optimized in a comparable way for the SuperQ 650M and QAE 550M chromatography materials.

20

Comparison of the linear DEAE 650M with the stepped NaCl gradient leads to an increase in the P450 BM-3 protein content in the elution peak, from 39% with the linear gradient to 84% with the stepped gradient. Comparable results were achieved with the 25 SuperQ 650M chromatography material; the QAE 550M chromatography material showed distinctly less good purification results. The yields in all cases with the stepped purification methods were > 78%; the highest yields of 93% of P450 BM-3 in the elution peak were obtained with DEAE 650S.

30

Example 2: Development of a spectroscopic activity detection for P450 BM-3 and P450 BM-3 F87A

The aim was to develop a spectrometric or fluorimetric activity 35 detection for P450 BM-3. Such an activity detection can, in contrast to standard methods such as HPLC or GC, be automated simply and thus be used for finding other P450 BM-3 enzyme variants.

40 In order to develop a novel activity detection for P450 BM-3, various compounds which carry the chromophore at the terminal C atom of the carboxylic acids were synthesized and investigated for their suitability.

45 Studies by Oliver et al. Biochemistry (1997), 36(7):1567 showed a shift in the hydroxylation profile by P450 BM-3 for lauric acid and myristic acid as substrate from subterminal positions to the

45

terminal position if phenylalanine at position 87 was replaced by alanine. To increase the sensitivity of the pNCA detection method, this point mutation was introduced as described in material and methods and confirmed by sequence analysis.

5

1. Detection principle

Figure 2 shows the principle of a spectrometric activity detection for terminally hydroxylating fatty acid hydroxylases.

10 After terminal hydroxylation there is formation of an unstable hemiacetal which dissociates into the ω -oxy carboxylic acid and the chromophore which can be detected spectrometrically.

2. Detection of P450 BM-3 F87A activity with PCA

15

a) Synthesis of the phenoxy carboxylic acids (PCA)

The PCA compounds were synthesized in a one-stage synthesis as described in Reference Example 5 starting from ω -bromo carboxylic acids. Overall yields between 76 and 78% were obtained in the syntheses. The PCAs were characterized by $^1\text{H-NMR}$, $^{13}\text{C-NMR}$ and melting point determination.

b) Choice of the reaction conditions

25

In order to be able to detect phenol formation by spectroscopy, it is obvious to measure the absorption in the wavelength range between 250 and 280 nm (Luchter-Wasylewska 1996). The low extinction coefficient at the absorption maximum at 274 nm of $\epsilon = 1090 \text{ M}^{-1}\text{cm}^{-1}$, the difference in the absorption characteristics of NADPH and NADP^+ in this wavelength range and the formation of hydrogen peroxide in uncoupled reactions prevented continuous spectroscopic measurement of phenol formation, however. For these reasons, the Merck phenol detection kit was used to quantify product formation. The conversion rates on use of the P450 BM-3 mutant F87A with NADPH as cofactor were found to be 640 eq/min for 12-PCA and 410 eq/min for 11-PCA.

3. Detection of P450 BM-3 and P450 BM-3 F87A activity with pNCA substratesa) Synthesis of the p-nitrophenoxy carboxylic acids (pNCA)

The pNCA compounds were synthesized in a novel, three-stage synthesis as described in Reference Example 5 starting from ω -bromo carboxylic acids by esterification, subsequent $\text{S}_{\text{N}}2$ reaction with sodium *p*-nitrophenolate and lipase-catalyzed

46

hydrolysis of the esters. The overall yields in the three-stage pNCA syntheses were between 61 and 69%. The pNCAs were characterized by ¹H-NMR, ¹³C-NMR and melting point determination.

5 b) Choice of the reaction conditions

Figure 2 describes the reaction principle for the conversion of pNCA substrates by P450 BM-3 and P450 BM-3 F87A. For the activity measurements it was necessary to optimize the pH and wavelength 10 of the spectroscopic detection system. Only deprotonated *p*-nitrophenolate (pKa 7.1) contributes to the yellow color; thus a pH > 9.1 (> 99% deprotonated) would be advisable for the sensitivity of detection. The pNCA compounds are stable in strongly alkaline solutions, in contrast to the P450 BM-3 protein 15 which loses 80% of its activity within 5 min at pH 10 and 30°C. A pH of 8.1 to 8.2 was chosen as a compromise between protein stability and sensitivity of the detection method. Calculations based on the Henderson-Hasselbalch equation show that in this pH range 90-92% of the converted *p*-nitrophenol are deprotonated and 20 contribute to the yellow color. The absorption maximum for *p*-nitrophenolate is at 400 nm. However, the heme site and the cofactor NADPH also absorb at this wavelength. P450 BM-3 has strong absorption characteristics between 350 and 450 nm which vary greatly as a function of substrate binding and the oxidation 25 state of the iron in the catalytic site. The absorption spectrum of NADPH limits the wavelength range to > 390 nm. The wavelength of 410 nm was eventually selected for the activity measurement on the basis of the reproducibility. If the sensitivity of the detection system is inadequate, wavelengths in the region of 30 400 nm should be used. The extinction coefficient was determined under the chosen detection conditions (pH 8.2, 410 nm) to be $\epsilon = 13,200 \text{ M}^{-1}\text{cm}^{-1}$.

pNCAs have only low solubility in water so that a solubilizer is 35 required. DMSO can be added for this purpose without influencing the P450 BM-3 F87A activity up to concentrations of 1% (v/v). 0.8% (v/v) DMSO was therefore used as solubilizer in the activity detection system.

40 The time required by the pNCA detection system depends greatly on the amount of enzyme used. If nmol amounts of P450 BM-3 F87A were employed in the pNCA activity detection, 1 min was sufficient for activity detection.

c) Automation of the pNCA detection

For use in an HTS environment, the pNCA activity detection was automated using a Biomek2000 workstation and a BMG FluoStar 5 microtiter plate reader. The reproducibility of the assay system was investigated using P450 BM-3 and the mutant F87A in 16 measurements in each case with the pNCA substrates 10-, 11-, 12- and 15-pNCA. There were differences by a factor of two to four in the total absorptions because of pipetting inaccuracies, but the 10 differences in reactivity varied only between 2 and 6%. The best reproducibility was achieved for the P450 BM-3 F87A mutant, with deviations of ~ 2%, and the worst were achieved for the wild type and 15-pNCA, with deviations of up to 6%, from the mean of all the measurements. The causes of the differences in accuracy are 15 the differences in the solubility of the pNCA substrates and different conversions depending on the chain length.

The F87A mutant converts 12-pNCA completely, whereas the wild-type enzyme stops after 33%. The cause is presumably the 20 subterminally hydroxylated 12-pNCA compounds which are no longer converted or are converted further only slowly. For P450 BM-3 and P450 BM-3 F87A, the pNCA chain-length profile and the conversion from ω -hydroxylation of the pNCAs, calculated from the ratios of the observed to the measured yellow coloration of the solution, 25 are summarized in Tables 4 and 5 below. In addition, the kinetic data were found from the Lineweaver-Burk diagrams for P450 F87A.

Table 4

30	Chain length of the pNCA compound	P450 BM-3 F87A k_{cat} [eq ^a /min]	P450 BM-3 F87A ω -hydroxylation products [%]	P450 BM-3 Wild type k_{cat} [eq ^a /min]	P450 BM-3 Wild type ω -hydroxylation products [%]
35	6	not converted	not converted	not converted	not converted
	8	1	<1	2	<1
	10	426	94	322	98
	11	204	64	267	63
40	12	574	100	114	33
	15	680	61	246	35

a Equivalent (eq) is used in place of the term nmol (substrate)/nmol (P450)

Table 5

5	Chain length of the pNCA compound	P450 BM-3 F87A k _{cat} [eq ^a /min]	K _m [mM]	k _{cat} /K _m [M ⁻¹ ·min ⁻¹]
10	10	426 32	42 8	1.0*10 ⁷
15	11	204 18	69 7	3.4*10 ⁵
20	12	574 47	6.2 0.3	1.1*10 ⁴
25	15	680	-	-

a Equivalent (eq) is used in place of the term nmol (substrate)/nmol (P450)

Example 3: Novel cofactor system for P450 BM-3 and P450 BM-3 F87A

A major impediment to the industrial use of P450 systems is the costs caused by the cofactor NADPH. To solve the cost problem, an alternative cofactor concept in which NADPH has been replaced by zinc and the mediator cobalt(III) sepulchrate has been developed; zinc serves as source of electrons and cobalt(III) sepulchrate serves as electron transport system from zinc to P450 BM-3.

1. Detection of the reduction of cobalt(III) sepulchrate by zinc

Under standard conditions, cobalt(III) sepulchrate has a normal potential of -0.54 V against a calomel electrode (Creaser et al., J. Am. Chem. Soc. (1977) 99: 3181). It can, as shown in Figure 3, be reduced by Zn dust in a Tris/HCl buffer (0.2 M, pH 8.2) within seconds. In the presence of atmospheric oxygen in aqueous solutions it is oxidized back to cobalt(III) sepulchrate within a few minutes.

2. Detection of P450 BM-3 F87A activity with alternative cofactor system

2.1 pNCA assay

Figure 4 shows the conversion of 12-pNCA by the Zn/cobalt(III) sepulchrate/P450 BM-3 F87A system. With a maximum absorption of 0.8 after 8 min, the Zn/cobalt(III) sepulchrate/P450 BM-3 F87A system shows a yellow color corresponding to 70% conversion. The yellow color caused by p-nitrophenolate disappears completely within 20 min; the residual absorption of 0.15 derives from the mediator. Control experiments showed that Zn powder reduces the nitro group of p-nitrophenolate in Tris/HCl buffer (pH 8.2,

50 mM, 0.25 M KCl). Further control experiments showed that hydrogen peroxide has no oxidative effect on *p*-nitrophenolate and pNCAs.

5 Figure 5 depicts the described electron transfer pathways from Zn via the mediator to P450 BM-3 and the substrate conversion taking account of the shortened hydrogen peroxide reaction pathway (shunt pathway).

10 2.2 PCA assay

Because of the reduction of *p*-nitrophenol by zinc in a Tris/HCl buffer, 12-pNCA was replaced by 12-PCA. The phenol was detected by a Merck phenol detection kit at 495 nm. A direct photometric 15 phenol detection at 274 nm is not possible owing to the absorption characteristics of the oxidized and reduced cobalt(III) sepulchrate. Figure 6 illustrates the slow decolorization of 12-PCA as substrate compared with 12-pNCA (Figure 4). It was possible to identify the cause of the decrease 20 in absorption as hydrogen peroxide which is formed by reduced cobalt(II) sepulchrate in side reactions by reduction of atmospheric oxygen in aqueous solutions. In addition, hydrogen peroxide formation always occurs as product of side reactions with P450 systems as a result of uncoupled reactions. For the 25 latter reason, further optimization of the PCA reaction conditions was not pursued further.

In the presence of 600 U of catalase, as shown in Figure 6, the decrease in absorption at 495 nm takes place distinctly more 30 slowly.

3.1 Buffer composition

In order to avoid decolorization of the solution through 35 reduction of *p*-nitrophenolate by zinc, initially, without success, the KCl concentration and the pH were varied within the scope of the stability of P450 BM-3 F87A (6.5-8.5). The reduction of *p*-nitrophenol by zinc can be successfully prevented, as shown in Figure 7, by additions of potassium phosphate buffer. There is 40 reduction of *p*-nitrophenol by Zn to only a small extent ($\leq 10\%$) with a potassium phosphate content $\geq 10\%$, and with a 1:1 mixture there is no further reduction detectable even after 14 h (not depicted). As shown in Figure 7, there is initially a marked reduction of about ~25% in the content of reduced Co(II) 45 sepulchrate in the mixing range up to 20% potassium phosphate, and it then remains constant between 60 and 70% with a potassium phosphate content between 20 and 70% (v/v). The lower

50

availability, compared with the Tris/HCl buffer system, of reduced cobalt(II) sepulchrate leads to a loss of about 15% of the activity.

5 From the above results, a 1:1 mixture of the two buffer solutions was used for further optimizations.

3.2 Effect of the mediator concentration on the conversion and the P450 BM-3 F87A activity

10

Figure 8A shows the effect of the cobalt(III) sepulchrate mediator on the P450 BM-3 activity in the NADPH assay with varying mediator concentrations. At cobalt(III) sepulchrate concentrations \geq 5 mM there was formation of a colloidal precipitate during the course of the reaction, and this was removed by centrifugation before the measurement of absorption. An optimal cobalt(III) sepulchrate concentration in the range 0.5-0.75 mM per 0.072 nmol of P450 BM-3 F87A is present for conversions with the zinc/cobalt(III) sepulchrate system. As shown in Figure 8B, cobalt(III) sepulchrate in concentrations up to \leq 0.5 mM inhibits P450 BM-3 F87A only slightly, even in the absence of substrate. The degree of inhibition remains constant with varying incubation times and depends only on the ratio of the cobalt(III) sepulchrate and P450 BM-3 F87A concentrations.

25

3.3 Zn concentration

The dependence of the conversion of 0.072 nmol of P450 BM-3 F87A on the amount of zinc powder employed is shown in Figure 9. An optimal conversion was achieved in the range from 20 to 40 mg of zinc per milliliter of reaction solution. Presumably a decrease in oxygen concentration in the reaction solution due to increasing mediator-catalyzed hydrogen peroxide formation was responsible for the declines in conversion with 50 and 100 mg.

35

Replacement of zinc powder by zinc granules led to only very low conversion rates (factor >20 lower) even on use of amounts 100 times higher.

40 3.4 Effect of the H₂O₂ concentration

In order to determine the amount of the contribution of hydrogen peroxide via the 'shunt' reaction pathway to the conversion of 12-pNCA by P450 BM-3 F87A, 12-pNCA and P450 BM-3 F87A were incubated with varying hydrogen peroxide concentrations. In the range 8-20 μ M hydrogen peroxide with comparable P450 BM-3 F87A activities a plateau is reached at 20-25% conversion,

51

irrespective of the hydrogen peroxide concentration, after one minute. Further addition of NADPH in excess (100 μ M) shows that P450 BM-3 F87A is not completely inactivated by hydrogen peroxide. The residual activities are high at low hydrogen peroxide concentration and decrease with increasing hydrogen peroxide concentration (not shown).

In order to determine the stability of P450 BM-3 toward hydrogen peroxide, P450 BM-3 F87A was incubated with varying amounts of hydrogen peroxide in the absence of substrate (12-pNCA) for 5 min. After addition of catalase (600 U) and 60 nmol of substrate, the conversion rates were determined using NADPH as electron donor.

As shown in Figure 10, in the absence of substrate, even hydrogen peroxide concentrations in the 5 μ M range distinctly inhibit the P450 BM-3 F87A activity. The consequence which emerges from this for a P450 BM-3 F87A enzyme membrane reactor is to operate at substrate concentrations which are as high as possible and to minimize the hydrogen peroxide formation by addition of catalase or antioxidant.

Example 4: Activity assay with further P450 BM-3 mutants

Further BM-3 mutants and the wild-type enzyme (WT) were assayed for activity on pNCA derivatives of varying chain length in analogy to Example 2. The results are summarized in Table 6 below:

Table 6

Specific activity of some P450 BM-3 mutants for pNCAs of varying chain length

	WT	F87A	L188K	V26T	R47F	S72G	A74G	M354T
15-pNCA	405 ¹	410	288	519	258	439	474	560
12-pNCA	141	284	316	555	233	596	517	480
10-pNCA	339	92	207	106	52	150	103	171
8-pNCA	15	2	69	16	13	3	6	4

¹ Specific activity: nmol/min/nmol P450.

SEQUENCE LISTING

<110> BASF Aktiengesellschaft

5 <120> Electron donor system for enzymes and its use in the biochemical conversion of substrates

<130> M/40076

10 <140>

<141>

<160> 35

15 <170> PatentIn Ver. 2.1

<210> 1

<211> 36

<212> DNA

<213> Artificial sequence

20 <220>

<223> Description of the artificial sequence:
Oligonucleotide for genomic *Bacillus megaterium* DNA

25 <400> 1
gtgaaagagg gatcccatga caattaaaga aatgcc 36

<210> 2

30 <211> 38

<212> DNA

<213> Artificial sequence

<220>

35 <223> Description of the artificial sequence:
Oligonucleotide for genomic *Bacillus megaterium* DNA

<400> 2
gcctcttgga tccttaccca gcccacacgt ctttgcg 38

40 <210> 3

<211> 19

<212> DNA

<213> Artificial sequence

45 <220>

56

<223> Description of the artificial sequence: Primer for sequencing

<400> 3

5 gtacgtgatt ttgcaggag

19

<210> 4

<211> 20

<212> DNA

10 <213> Artificial sequence

<220>

<223> Description of the artificial sequence: Primer for sequencing

15

<400> 4

ggctatcatg cgatgatgg

20

<210> 5

20 <211> 19

<212> DNA

<213> Artificial sequence

<220>

25 <223> Description of the artificial sequence: Primer for sequencing

<400> 5

cccagcttat gatgaaaac

19

30

<210> 6

<211> 20

<212> DNA

<213> Artificial sequence

35

<220>

<223> Description of the artificial sequence: Primer for sequencing

<400> 6

40 ggaaaagatc cagaaacggg

20

<210> 7

<211> 19

45 <212> DNA

<213> Artificial sequence

<220>

57

<223> Description of the artificial sequence: Primer for sequencing

<400> 7

5 gtcggcatgg tcttaaacg

19

<210> 8

<211> 20

<212> DNA

10 <213> Artificial sequence

<220>

<223> Description of the artificial sequence: Primer for sequencing

15 <400> 8

attcctcagc ttcaccgtga

20

<210> 9

20 <211> 19

<212> DNA

<213> Artificial sequence

<220>

25 <223> Description of the artificial sequence: Primer for sequencing

<400> 9

cttggcggta ttccttcac

19

30

<210> 10

<211> 20

<212> DNA

<213> Artificial sequence

35 <220>

<223> Description of the artificial sequence: Primer for sequencing

<400> 10

atttgcacccg caggtcgcaa

20

40

<210> 11

<211> 17

<212> DNA

45 <213> Artificial sequence

<220>

58

<223> Description of the artificial sequence: Primer for sequencing

<400> 11

5 ctgggctact acgtatc

17

<210> 12

<211> 20

<212> DNA

10 <213> Artificial sequence

<220>

<223> Description of the artificial sequence: Primer for sequencing

15 <400> 12

ttcaatttgt cgacagcgcc

20

<210> 13

20 <211> 19

<212> DNA

<213> Artificial sequence

<220>

25 <223> Description of the artificial sequence: Primer for sequencing

<400> 13

gaaggagatc atttaggtg

19

30

<210> 14

<211> 20

<212> DNA

<213> Artificial sequence

35 <220>

<223> Description of the artificial sequence: Primer for sequencing

<400> 14

40 tcgcgcaatg gctgctaaaa

20

<210> 15

<211> 18

45 <212> DNA

<213> Artificial sequence

<220>

59

<223> Description of the artificial sequence: Primer for sequencing

<400> 15

5 cgatttcttc atcacctc

18

<210> 16

<211> 20

<212> DNA

10 <213> Artificial sequence

<220>

<223> Description of the artificial sequence: Primer for sequencing

15 <400> 16

ctgccaataaag accctgaaac

20

<210> 17

20 <211> 20

<212> DNA

<213> Artificial sequence

<220>

25 <223> Description of the artificial sequence: Primer for sequencing

<400> 17

accatcatcg catgatagcc

20

30 <210> 18

<211> 20

<212> DNA

<213> Artificial sequence

35 <220>

<223> Description of the artificial sequence: Primer for sequencing

<400> 18

cccgtttctg gatctttcc

20

40

<210> 19

<211> 20

<212> DNA

45 <213> Artificial sequence

60

<220>
<223> Description of the artificial sequence: Primer for sequencing

5 <400> 19
tcacggtgaa gctgaggaat 20

<210> 20
<211> 20
10 <212> DNA
<213> Artificial sequence

<220>
<223> Description of the artificial sequence: Primer for sequencing

15 <400> 20
ttgcgacctg cggtgcaaat 20

20 <210> 21
<211> 20
<212> DNA
<213> Artificial sequence

25 <220>
<223> Description of the artificial sequence: Primer for sequencing

<400> 21
ggcgctgtcg acaaattgaa 20

30 <210> 22
<211> 20
<212> DNA
35 <213> Artificial sequence

<220>
<223> Description of the artificial sequence: Primer for sequencing

40 <400> 22
tttagcagc cattgcgcga 20

<210> 23
45 <211> 20
<212> DNA
<213> Artificial sequence

61

<220>

<223> Description of the artificial sequence: Primer for sequencing

5 <400> 23

gtttcagggt cttttggcag

20

<210> 24

<211> 36

10 <212> DNA

<213> Artificial sequence

<220>

<223> Description of the artificial sequence:
15 Oligonucleotide for tag at C terminus

<400> 24

gtgaaagagg gatccatga caattaaaga aatgcc

36

20 <210> 25

<211> 42

<212> DNA

<213> Artificial sequence

25 <220>

<223> Description of the artificial sequence:
Oligonucleotide for tag at C terminus

<400> 25

cggaattctt aacgacgacg acgacgacgc ccagcccaca cg

42

30

<210> 26

<211> 36

<212> DNA

35 <213> Artificial sequence

<220>

<223> Description of the artificial sequence:
Oligonucleotide for tag at C terminus

40 <400> 26

gtgaaagagg gatccatga caattaaaga aatgcc

36

<210> 27

<211> 42

45 <212> DNA

<213> Artificial sequence

62

<220>
<223> Description of the artificial sequence:
Oligonucleotide for tag at C terminus

5 <400> 27
cggaattctt attcttcttc ttcttcttcc ccagcccaaca cg 42

<210> 28
<211> 36
10 <212> DNA
<213> Artificial sequence

<220>
<223> Description of the artificial sequence:
15 Oligonucleotide for tag at C terminus

<400> 28
gtgaaagagg gatcccatga caattaaaga aatgcc 36

20 <210> 29
<211> 42
<212> DNA
<213> Artificial sequence

25 <220>
<223> Description of the artificial sequence:
Oligonucleotide for tag at C terminus

<400> 29
cgcaattctt aatgatgatg atgatgatgc ccagcccaaca cg 42
30

<210> 30
<211> 38
<212> DNA
35 <213> Artificial sequence

<220>
<223> Description of the artificial sequence:
Oligonucleotide for tag at C terminus

40 <400> 30
gtctcagcgt gagacccca gcccacacgt ctttgcc 38

45 <210> 31
<211> 36
<212> DNA
<213> Artificial sequence

63

<220>

<223> Description of the artificial sequence:
Oligonucleotide for tag at C terminus

5 <400> 31

gtgaaagagg tctccaatga caattaaaga aatgcc

36

<210> 32

<211> 34

10 <212> DNA

<213> Artificial sequence

<220>

<223> Description of the artificial sequence: Primer for
15 P450 BM-3 point mutant F87A

<400> 32

gcaggagacg gggtggccac aagctggacg catg

34

20 <210> 33

<211> 34

<212> DNA

<213> Artificial sequence

25 <220>

<223> Description of the artificial sequence: Primer for
P450 BM-3 point mutant F87A

<400> 33

catgcgtcca gcttgtggcc aaccgggtctc ctgc

34

30

<210> 34

<211> 3150

<212> DNA

<213> Bacillus megaterium

35 <220>

<221> CDS

<222> (4)..(3150)

<400> 34

40 atg aca att aaa gaa atg cct cag cca aaa acg ttt gga gag ctt aaa 48
Thr Ile Lys Glu Met Pro Gln Pro Lys Thr Phe Gly Glu Leu Lys
1 5 10 1545 aat tta ccg tta tta aac aca gat aaa ccg gtt caa gct ttg atg aaa 96
Asn Leu Pro Leu Leu Asn Thr Asp Lys Pro Val Gln Ala Leu Met Lys
20 25 30

att gcg gat gaa tta gga gaa atc ttt aaa ttc gag gcg cct ggt cgt 144

64

Ile Ala Asp Glu Leu Gly Glu Ile Phe Lys Phe Glu Ala Pro Gly Arg
 35 40 45

5 gta acg cgc tac tta tca agt cag cgt cta att aaa gaa gca tgc gat 192
 Val Thr Arg Tyr Leu Ser Ser Gln Arg Leu Ile Lys Glu Ala Cys Asp
 50 55 60

10 gaa tca cgc ttt gat aaa aac tta agt caa gcg ctt aaa ttt gta cgt 240
 Glu Ser Arg Phe Asp Lys Asn Leu Ser Gln Ala Leu Lys Phe Val Arg
 65 70 75

15 gat ttt gca gga gac ggg tta ttt aca agc tgg acg cat gaa aaa aat 288
 Asp Phe Ala Gly Asp Gly Leu Phe Thr Ser Trp Thr His Glu Lys Asn
 80 85 90 95

20 tgg aaa aaa gcg cat aat atc tta ctt cca agc ttc agt cag cag gca 336
 Trp Lys Lys Ala His Asn Ile Leu Leu Pro Ser Phe Ser Gln Gln Ala
 100 105 110

25 atg aaa ggc tat cat gcg atg atg gtc gat atc gcc gtg cag ctt gtt 384
 Met Lys Gly Tyr His Ala Met Met Val Asp Ile Ala Val Gln Leu Val
 115 120 125

30 caa aag tgg gag cgt cta aat gca gat gag cat att gaa gta ccg gaa 432
 Gln Lys Trp Glu Arg Leu Asn Ala Asp Glu His Ile Glu Val Pro Glu
 130 135 140

35 gac atg aca cgt tta acg ctt gat aca att ggt ctt tgc ggc ttt aac 480
 Asp Met Thr Arg Leu Thr Leu Asp Thr Ile Gly Leu Cys Gly Phe Asn
 145 150 155

40 tat cgc ttt aac agc ttt tac cga gat cag cct cat cca ttt att aca 528
 Tyr Arg Phe Asn Ser Phe Tyr Arg Asp Gln Pro His Pro Phe Ile Thr
 160 165 170 175

45 agt atg gtc cgt gca ctg gat gaa gca atg aac aag ctg cag cga gca 576
 Ser Met Val Arg Ala Leu Asp Glu Ala Met Asn Lys Leu Gln Arg Ala
 180 185 190

50 aat cca gac gac cca gct tat gat gaa aac aag cgc cag ttt caa gaa 624
 Asn Pro Asp Asp Pro Ala Tyr Asp Glu Asn Lys Arg Gln Phe Gln Glu
 195 200 205

55 gat atc aag gtc atg aac gac cta gta gat aaa att att gca gat cgc 672
 Asp Ile Lys Val Met Asn Asp Leu Val Asp Lys Ile Ile Ala Asp Arg
 210 215 220

60 aaa gca agc ggt gaa caa agc gat gat tta tta acg cat atg cta aac 720
 Lys Ala Ser Gly Glu Gln Ser Asp Asp Leu Leu Thr His Met Leu Asn
 225 230 235

65 gga aaa gat cca gaa acg ggt gag ccg ctt gat gac gag aac att cgc 768

0050/50531

CA 02379518 2002-01-23

65

Gly Lys Asp Pro Glu Thr Gly Glu Pro Leu Asp Asp Glu Asn Ile Arg
 240 245 250 255
 tat caa att att aca ttc tta att gcg gga cac gaa aca aca agt ggt 816
 5 Tyr Gln Ile Ile Thr Phe Leu Ile Ala Gly His Glu Thr Thr Ser Gly
 260 265 270
 ctt tta tca ttt gcg ctg tat ttc tta gtg aaa aat cca cat gta tta 864
 Leu Leu Ser Phe Ala Leu Tyr Phe Leu Val Lys Asn Pro His Val Leu
 275 280 285
 10 caa aaa gca gca gaa gaa gca gca cga gtt cta gta gat cct gtt cca 912
 Gln Lys Ala Ala Glu Glu Ala Ala Arg Val Leu Val Asp Pro Val Pro
 290 295 300
 15 agc tac aaa caa gtc aaa cag ctt aaa tat gtc ggc atg gtc tta aac 960
 Ser Tyr Lys Gln Val Lys Gln Leu Lys Tyr Val Gly Met Val Leu Asn
 305 310 315
 gaa gcg ctg cgc tta tgg cca act gct cct gcg ttt tcc cta tat gca 1008
 Glu Ala Leu Arg Leu Trp Pro Thr Ala Pro Ala Phe Ser Leu Tyr Ala
 20 320 325 330 335
 aaa gaa gat acg gtg ctt gga gga gaa tat cct tta gaa aaa ggc gac 1056
 Lys Glu Asp Thr Val Leu Gly Gly Glu Tyr Pro Leu Glu Lys Gly Asp
 340 345 350
 25 gaa cta atg gtt ctg att cct cag ctt cac cgt gat aaa aca att tgg 1104
 Glu Leu Met Val Leu Ile Pro Gln Leu His Arg Asp Lys Thr Ile Trp
 355 360 365
 gga gac gat gtg gaa gag ttc cgt cca gag cgt ttt gaa aat cca agt 1152
 30 Gly Asp Asp Val Glu Glu Phe Arg Pro Glu Arg Phe Glu Asn Pro Ser
 370 375 380
 gcg att ccg cag cat gcg ttt aaa ccg ttt gga aac ggt cag cgt gcg 1200
 Ala Ile Pro Gln His Ala Phe Lys Pro Phe Gly Asn Gly Gln Arg Ala
 35 385 390 395
 tgt atc ggt cag cag ttc gct ctt cat gaa gca acg ctg gta ctt ggt 1248
 Cys Ile Gly Gln Gln Phe Ala Leu His Glu Ala Thr Leu Val Leu Gly
 400 405 410 415
 40 atg atg cta aaa cac ttt gac ttt gaa gat cat aca aac tac gag ctg 1296
 Met Met Leu Lys His Phe Asp Phe Glu Asp His Thr Asn Tyr Glu Leu
 420 425 430
 gat att aaa gaa act tta acg tta aaa cct gaa ggc ttt gtg gta aaa 1344
 45 Asp Ile Lys Glu Thr Leu Thr Leu Lys Pro Glu Gly Phe Val Val Lys
 435 440 445
 gca aaa tcg aaa aaa att ccg ctt ggc ggt att cct tca cct agc act 1392

66

Ala Lys Ser Lys Lys Ile Pro Leu Gly Gly Ile Pro Ser Pro Ser Thr
 450 455 460

5 gaa cag tct gct aaa aaa gta cgc aaa aag gca gaa aac gct cat aat 1440
 Glu Gln Ser Ala Lys Lys Val Arg Lys Lys Ala Glu Asn Ala His Asn
 465 470 475

10 acg ccg ctg ctt gtg cta tac ggt tca aat atg gga aca gct gaa gga 1488
 Thr Pro Leu Leu Val Leu Tyr Gly Ser Asn Met Gly Thr Ala Glu Gly
 480 485 490 495

15 acg gcg cgt gat tta gca gat att gca atg agc aaa gga ttt gca ccg 1536
 Thr Ala Arg Asp Leu Ala Asp Ile Ala Met Ser Lys Gly Phe Ala Pro
 500 505 510

20 cag gtc gca acg ctt gat tca cac gcc gga aat ctt ccg cgc gaa gga 1584
 Gln Val Ala Thr Leu Asp Ser His Ala Gly Asn Leu Pro Arg Glu Gly
 515 520 525

25 gct gta tta att gta acg gcg tct tat aac ggt cat ccg cct gat aac 1632
 Ala Val Leu Ile Val Thr Ala Ser Tyr Asn Gly His Pro Pro Asp Asn
 530 535 540

30 gca aag caa ttt gtc gac tgg tta gac caa gcg tct gct gat gaa gta 1680
 Ala Lys Gln Phe Val Asp Trp Leu Asp Gln Ala Ser Ala Asp Glu Val
 545 550 555

35 aaa ggc gtt cgc tac tcc gta ttt gga tgc ggc gat aaa aac tgg gct 1728
 Lys Gly Val Arg Tyr Ser Val Phe Gly Cys Gly Asp Lys Asn Trp Ala
 560 565 570 575

40 act acg tat caa aaa gtg cct gct ttt atc gat gaa acg ctt gcc gct 1776
 Thr Thr Tyr Gln Lys Val Pro Ala Phe Ile Asp Glu Thr Leu Ala Ala
 580 585 590

45 aaa ggg gca gaa aac atc gct gac cgc ggt gaa gca gat gca agc gac 1824
 Lys Gly Ala Glu Asn Ile Ala Asp Arg Gly Glu Ala Asp Ala Ser Asp
 595 600 605

50 gac ttt gaa ggc aca tat gaa gaa tgg cgt gaa cat atg tgg agt gac 1872
 Asp Phe Glu Gly Thr Tyr Glu Glu Trp Arg Glu His Met Trp Ser Asp
 610 615 620

55 gta gca gcc tac ttt aac ctc gac att gaa aac agt gaa gat aat aaa 1920
 Val Ala Ala Tyr Phe Asn Leu Asp Ile Glu Asn Ser Glu Asp Asn Lys
 625 630 635

60 tct act ctt tca ctt caa ttt gtc gac agc gcc gcg gat atg ccg ctt 1968
 Ser Thr Leu Ser Leu Gln Phe Val Asp Ser Ala Ala Asp Met Pro Leu
 640 645 650 655

65 gcg aaa atg cac ggt gcg ttt tca acg aac gtc gta gca agc aaa gaa 2016

67

Ala Lys Met His Gly Ala Phe Ser Thr Asn Val Val Ala Ser Lys Glu
 660 665 670

5 ctt caa cag cca ggc agt gca cga agc acg cga cat ctt gaa att gaa 2064
 Leu Gln Gln Pro Gly Ser Ala Arg Ser Thr Arg His Leu Glu Ile Glu
 675 680 685

ctt cca aaa gaa gct tct tat caa gaa gga gat cat tta ggt gtt att 2112
 Leu Pro Lys Glu Ala Ser Tyr Gln Glu Gly Asp His Leu Gly Val Ile
 690 695 700

10 cct cgc aac tat gaa gga ata gta aac cgt gta aca gca agg ttc ggc 2160
 Pro Arg Asn Tyr Glu Gly Ile Val Asn Arg Val Thr Ala Arg Phe Gly
 705 710 715

15 cta gat gca tca cag caa atc cgt ctg gaa gca gaa gaa aaa tta 2208
 Leu Asp Ala Ser Gln Gln Ile Arg Leu Glu Ala Glu Glu Lys Leu
 720 725 730 735

20 gct cat ttg cca ctc gct aaa aca gta tcc gta gaa gag ctt ctg caa 2256
 Ala His Leu Pro Leu Ala Lys Thr Val Ser Val Glu Glu Leu Leu Gln
 740 745 750

tac gtg gag ctt caa gat cct gtt acg cgc acg cag ctt cgc gca atg 2304
 Tyr Val Glu Leu Gln Asp Pro Val Thr Arg Thr Gln Leu Arg Ala Met
 755 760 765

25 gct gct aaa acg gtc tgc ccg ccg cat aaa gta gag ctt gaa gcc ttg 2352
 Ala Ala Lys Thr Val Cys Pro Pro His Lys Val Glu Leu Glu Ala Leu
 770 775 780

30 ctt gaa aag caa gcc tac aaa gaa caa gtg ctg gca aaa cgt tta aca 2400
 Leu Glu Lys Gln Ala Tyr Lys Glu Gln Val Leu Ala Lys Arg Leu Thr
 785 790 795

35 atg ctt gaa ctg ctt gaa aaa tac ccg gcg tgt gaa atg aaa ttc agc 2448
 Met Leu Glu Leu Leu Glu Lys Tyr Pro Ala Cys Glu Met Lys Phe Ser
 800 805 810 815

gaa ttt atc gcc ctt ctg cca agc ata cgc ccg cgc tat tac tcg att 2496
 Glu Phe Ile Ala Leu Leu Pro Ser Ile Arg Pro Arg Tyr Tyr Ser Ile
 820 825 830

40 tct tca tca cct cgt gtc gat gaa aaa caa gca agc atc acg gtc agc 2544
 Ser Ser Ser Pro Arg Val Asp Glu Lys Gln Ala Ser Ile Thr Val Ser
 835 840 845

45 gtt gtc tca gga gaa gcg tgg agc gga tat gga gaa tat aaa gga att 2592
 Val Val Ser Gly Glu Ala Trp Ser Gly Tyr Gly Glu Tyr Lys Gly Ile
 850 855 860

gcg tcg aac tat ctt gcc gag ctg caa gaa gga gat acg att acg tgc 2640

68

Ala Ser Asn Tyr Leu Ala Glu Leu Gln Glu Gly Asp Thr Ile Thr Cys
 865 870 875

ttt att tcc aca ccg cag tca gaa ttt acg ctg cca aaa gac cct gaa 2688
 5 Phe Ile Ser Thr Pro Gln Ser Glu Phe Thr Leu Pro Lys Asp Pro Glu
 880 885 890 895

acg ccg ctt atc atg gtc gga ccg gga aca ggc gtc gcg ccg ttt aga 2736
 Thr Pro Leu Ile Met Val Gly Pro Gly Thr Gly Val Ala Pro Phe Arg
 900 905 910

10 ggc ttt gtg cag gcg cgc aaa cag cta aaa gaa caa gga cag tca ctt 2784
 Gly Phe Val Gln Ala Arg Lys Gln Leu Lys Glu Gln Gly Gln Ser Leu
 915 920 925

15 gga gaa gca cat tta tac ttc ggc tgc cgt tca cct cat gaa gac tat 2832
 Gly Glu Ala His Leu Tyr Phe Gly Cys Arg Ser Pro His Glu Asp Tyr
 930 935 940

20 ctg tat caa gaa gag ctt gaa aac gcc caa agc gaa ggc atc att acg 2880
 Leu Tyr Gln Glu Glu Leu Glu Asn Ala Gln Ser Glu Gly Ile Ile Thr
 945 950 955

25 ctt cat acc gct ttt tct cgc atg cca aat cag ccg aaa aca tac gtt 2928
 Leu His Thr Ala Phe Ser Arg Met Pro Asn Gln Pro Lys Thr Tyr Val
 960 965 970 975

30 cag cac gta atg gaa caa gac ggc aag aaa ttg att gaa ctt ctt gat 2976
 Gln His Val Met Glu Gln Asp Gly Lys Lys Leu Ile Glu Leu Leu Asp
 980 985 990

35 caa gga gcg cac ttc tat att tgc gga gac gga agc caa atg gca cct 3024
 Gln Gly Ala His Phe Tyr Ile Cys Gly Asp Gly Ser Gln Met Ala Pro
 995 1000 1005

40 gcc gtt gaa gca acg ctt atg aaa agc tat gct gac gtt cac caa gtg 3072
 Ala Val Glu Ala Thr Leu Met Lys Ser Tyr Ala Asp Val His Gln Val
 1010 1015 1020

45 agt gaa gca gac gct cgc tta tgg ctg cag cag cta gaa gaa aaa ggc 3120
 Ser Glu Ala Asp Ala Arg Leu Trp Leu Gln Gln Leu Glu Glu Lys Gly
 1025 1030 1035

40 cga tac gca aaa gac gtg tgg gct ggg taa 3150
 Arg Tyr Ala Lys Asp Val Trp Ala Gly
 1040 1045

45 <210> 35
 <211> 1048
 <212> PRT
 <213> *Bacillus megaterium*

69

<400> 35

Thr Ile Lys Glu Met Pro Gln Pro Lys Thr Phe Gly Glu Leu Lys Asn
1 5 10 155 Leu Pro Leu Leu Asn Thr Asp Lys Pro Val Gln Ala Leu Met Lys Ile
20 25 30Ala Asp Glu Leu Gly Glu Ile Phe Lys Phe Glu Ala Pro Gly Arg Val
35 40 4510 Thr Arg Tyr Leu Ser Ser Gln Arg Leu Ile Lys Glu Ala Cys Asp Glu
50 55 60Ser Arg Phe Asp Lys Asn Leu Ser Gln Ala Leu Lys Phe Val Arg Asp
15 65 70 75 80Phe Ala Gly Asp Gly Leu Phe Thr Ser Trp Thr His Glu Lys Asn Trp
85 90 95Lys Lys Ala His Asn Ile Leu Leu Pro Ser Phe Ser Gln Gln Ala Met
20 100 105 110Lys Gly Tyr His Ala Met Met Val Asp Ile Ala Val Gln Leu Val Gln
115 120 12525 Lys Trp Glu Arg Leu Asn Ala Asp Glu His Ile Glu Val Pro Glu Asp
130 135 140Met Thr Arg Leu Thr Leu Asp Thr Ile Gly Leu Cys Gly Phe Asn Tyr
145 150 155 16030 Arg Phe Asn Ser Phe Tyr Arg Asp Gln Pro His Pro Phe Ile Thr Ser
165 170 175Met Val Arg Ala Leu Asp Glu Ala Met Asn Lys Leu Gln Arg Ala Asn
180 185 19035 Pro Asp Asp Pro Ala Tyr Asp Glu Asn Lys Arg Gln Phe Gln Glu Asp
195 200 205Ile Lys Val Met Asn Asp Leu Val Asp Lys Ile Ile Ala Asp Arg Lys
210 215 22040 Ala Ser Gly Glu Gln Ser Asp Asp Leu Leu Thr His Met Leu Asn Gly
225 230 235 240Lys Asp Pro Glu Thr Gly Glu Pro Leu Asp Asp Glu Asn Ile Arg Tyr
45 245 250 255Gln Ile Ile Thr Phe Leu Ile Ala Gly His Glu Thr Thr Ser Gly Leu
260 265 270

70

Leu Ser Phe Ala Leu Tyr Phe Leu Val Lys Asn Pro His Val Leu Gln
275 280 285

5 Lys Ala Ala Glu Glu Ala Ala Arg Val Leu Val Asp Pro Val Pro Ser
290 295 300

Tyr Lys Gln Val Lys Gln Leu Lys Tyr Val Gly Met Val Leu Asn Glu
305 310 315 320

10 Ala Leu Arg Leu Trp Pro Thr Ala Pro Ala Phe Ser Leu Tyr Ala Lys
325 330 335

Glu Asp Thr Val Leu Gly Gly Glu Tyr Pro Leu Glu Lys Gly Asp Glu
340 345 350

15 Leu Met Val Leu Ile Pro Gln Leu His Arg Asp Lys Thr Ile Trp Gly
355 360 365

Asp Asp Val Glu Glu Phe Arg Pro Glu Arg Phe Glu Asn Pro Ser Ala
370 375 380

20 Ile Pro Gln His Ala Phe Lys Pro Phe Gly Asn Gly Gln Arg Ala Cys
385 390 395 400

Ile Gly Gln Gln Phe Ala Leu His Glu Ala Thr Leu Val Leu Gly Met
405 410 415

Met Leu Lys His Phe Asp Phe Glu Asp His Thr Asn Tyr Glu Leu Asp
420 425 430

Ile Lys Glu Thr Leu Thr Leu Lys Pro Glu Gly Phe Val Val Lys Ala
435 440 445

Lys Ser Lys Lys Ile Pro Leu Gly Gly Ile Pro Ser Pro Ser Thr Glu
450 455 460

35 Gln Ser Ala Lys Lys Val Arg Lys Lys Ala Glu Asn Ala His Asn Thr
465 470 475 480

Pro Leu Leu Val Leu Tyr Gly Ser Asn Met Gly Thr Ala Glu Gly Thr
485 490 495

40 Ala Arg Asp Leu Ala Asp Ile Ala Met Ser Lys Gly Phe Ala Pro Gln
500 505 510

Val Ala Thr Leu Asp Ser His Ala Gly Asn Leu Pro Arg Glu Gly Ala
515 520 525

45 Val Leu Ile Val Thr Ala Ser Tyr Asn Gly His Pro Pro Asp Asn Ala
530 535 540

71

Lys Gln Phe Val Asp Trp Leu Asp Gln Ala Ser Ala Asp Glu Val Lys
545 550 555 560

Gly Val Arg Tyr Ser Val Phe Gly Cys Gly Asp Lys Asn Trp Ala Thr
5 565 570 575

Thr Tyr Gln Lys Val Pro Ala Phe Ile Asp Glu Thr Leu Ala Ala Lys
580 585 590

Gly Ala Glu Asn Ile Ala Asp Arg Gly Glu Ala Asp Ala Ser Asp Asp
10 595 600 605

Phe Glu Gly Thr Tyr Glu Glu Trp Arg Glu His Met Trp Ser Asp Val
610 615 620

Ala Ala Tyr Phe Asn Leu Asp Ile Glu Asn Ser Glu Asp Asn Lys Ser
15 625 630 635 640

Thr Leu Ser Leu Gln Phe Val Asp Ser Ala Ala Asp Met Pro Leu Ala
645 650 655

Lys Met His Gly Ala Phe Ser Thr Asn Val Val Ala Ser Lys Glu Leu
20 660 665 670

Gln Gln Pro Gly Ser Ala Arg Ser Thr Arg His Leu Glu Ile Glu Leu
675 680 685

25 Pro Lys Glu Ala Ser Tyr Gln Glu Gly Asp His Leu Gly Val Ile Pro
690 695 700

Arg Asn Tyr Glu Gly Ile Val Asn Arg Val Thr Ala Arg Phe Gly Leu
705 710 715 720

30 Asp Ala Ser Gln Gln Ile Arg Leu Glu Ala Glu Glu Lys Leu Ala
725 730 735

His Leu Pro Leu Ala Lys Thr Val Ser Val Glu Glu Leu Leu Gln Tyr
35 740 745 750

Val Glu Leu Gln Asp Pro Val Thr Arg Thr Gln Leu Arg Ala Met Ala
755 760 765

Ala Lys Thr Val Cys Pro Pro His Lys Val Glu Leu Glu Ala Leu Leu
40 770 775 780

Glu Lys Gln Ala Tyr Lys Glu Gln Val Leu Ala Lys Arg Leu Thr Met
785 790 795 800

45 Leu Glu Leu Leu Glu Lys Tyr Pro Ala Cys Glu Met Lys Phe Ser Glu
805 810 815

Phe Ile Ala Leu Leu Pro Ser Ile Arg Pro Arg Tyr Tyr Ser Ile Ser

72
820 825 830
Ser Ser Pro Arg Val Asp Glu Lys Gln Ala Ser Ile Thr Val Ser Val
835 840 845
5 Val Ser Gly Glu Ala Trp Ser Gly Tyr Gly Glu Tyr Lys Gly Ile Ala
850 855 860
Ser Asn Tyr Leu Ala Glu Leu Gln Glu Gly Asp Thr Ile Thr Cys Phe
865 870 875 880
10 Ile Ser Thr Pro Gln Ser Glu Phe Thr Leu Pro Lys Asp Pro Glu Thr
885 890 895
Pro Leu Ile Met Val Gly Pro Gly Thr Gly Val Ala Pro Phe Arg Gly
15 900 905 910
Phe Val Gln Ala Arg Lys Gln Leu Lys Glu Gln Gly Gln Ser Leu Gly
915 920 925
Glu Ala His Leu Tyr Phe Gly Cys Arg Ser Pro His Glu Asp Tyr Leu
20 930 935 940
Tyr Gln Glu Glu Leu Glu Asn Ala Gln Ser Glu Gly Ile Ile Thr Leu
945 950 955 960
25 His Thr Ala Phe Ser Arg Met Pro Asn Gln Pro Lys Thr Tyr Val Gln
965 970 975
His Val Met Glu Gln Asp Gly Lys Lys Leu Ile Glu Leu Leu Asp Gln
980 985 990
30 Gly Ala His Phe Tyr Ile Cys Gly Asp Gly Ser Gln Met Ala Pro Ala
995 1000 1005
Val Glu Ala Thr Leu Met Lys Ser Tyr Ala Asp Val His Gln Val Ser
1010 1015 1020
35 Glu Ala Asp Ala Arg Leu Trp Leu Gln Gln Leu Glu Glu Lys Gly Arg
1025 1030 1035 1040
Tyr Ala Lys Asp Val Trp Ala Gly
1045
40

We claim:

1. An electron donor system for transferring electrons to enzymes with redox properties, wherein the system comprises an inorganic, non-electrode-bound source of electrons and a mediator which is able to transfer electrons from the source of electrons to the enzyme.
5
- 10 2. An electron donor system as claimed in claim 1, wherein the enzyme is a cytochrome P450-containing enzyme.
- 15 3. An electron donor system as claimed in claim 2, wherein the enzyme is a monooxygenase (E.C. 1.14.-.-).
4. An electron donor system as claimed in any of the preceding claims, wherein the mediator has a standard normal potential in the region of less than about -0.4 V.
- 20 5. An electron donor system as claimed in any of the preceding claims, wherein the mediator is selected from cobalt(III) sepulchrate, methylviologen, neutral red, riboflavin, ruthenium triacetate, FMN and FAD.
- 25 6. An electron donor system as claimed in any of the preceding claims, wherein the source of electrons is a metal with a lower standard normal potential than the mediator.
7. An electron donor system as claimed in claim 6, wherein the source of electrons is metallic zinc.
30
8. An electron donor system as claimed in any of the preceding claims, selected from the systems:
 - 35 - Zn/cobalt(III) sepulchrate and
 - Zn/neutral red.
9. A method for the enzymatic transfer of oxygen to a hydrocarbon-containing hydrogen donor molecule, which comprises incubating the hydrogen donor molecule in a reaction medium comprising the oxygen-transferring enzyme and an electron donor system as claimed in any of claims 1 to 8 in the presence of oxygen under reaction conditions.
40
- 45 10. A method as claimed in claim 9, wherein the hydrogen donor molecule is selected from compounds of the formula

53

R-X

in which

5 R is an alkyl radical with 8 or more carbon atoms, and

 X is a polar group capable of forming hydrogen bonds,
 preferably a carboxyl, amide, nitrile, sulfate, sulfone,
 amine or hydroxyl group.

10

11. A method for the enzymatic production of terminally or
 subterminally (position ω -1 to ω -4) hydroxylated fatty acids,
 which comprises

15 a) converting a hydroxylatable fatty acid or fatty acid
 derivative in the presence of an electron donor system as
 claimed in any of claims 1 to 8 using a cytochrome P450
 monooxygenase and oxygen; and

20 b) isolating the hydroxylated product(s).

12. A method as claimed in claim 11, wherein the ω -hydroxylatable
 fatty acid derivative is selected from terminally saturated,
 branched or unbranched fatty acids with more than 10 carbon
25 atoms, in particular C₁₂ - C₃₀ fatty acids.

13. A method as claimed in any of claims 9 to 12, wherein the
 enzyme is a cytochrome P450 monooxygenase selected from:

30 a) the wild-type enzyme which can be isolated from *Bacillus*
 megaterium (DSM 32T); or

 b) a mutant, which can be obtained by amino acid
 substitution in at least one of positions 26, 47, 72, 74,
35 87, 188 and 354, of the wild-type enzyme (SEQ ID NO: 35).

14. A method as claimed in claim 13, wherein a single mutant
 selected from F87A, F87V, L188K, V26T, R47F, S27G, A74G and
 M354T is employed.

40

15. A method as claimed in claim 13, wherein the mutant has in
 position 87 the mutation F87A or F87V and at least one other
 of the following mutations: L188K, A74G, R47F and V26T.

45 16. A method as claimed in any of claims 11 to 15, wherein the
 electron donor system is zinc/Co(III) sepulchrate.

54

17. A method as claimed in any of claims 11 to 16, wherein at least stage a) is carried out in the presence of chloride ions.

5 18. A method as claimed in any of claims 11 to 17, wherein at least stage a) is carried out in the presence of a hydrogen peroxide-cleaving enzyme.

19. A bioreactor for use for producing ω -hydroxylated fatty acids, which comprises immobilized monooxygenase and an electron donor system as claimed in any of claims 1 to 8 in a liquid reaction medium.

15 20. A detection method for fatty acid monooxygenases, which comprises

20 a) incubating an analyte suspected of having enzymic activity with an ω -hydroxylatable fatty acid or fatty acid derivative which has a terminal chromophore or fluorophore which can be eliminated, in the presence of an electron donor system as claimed in any of claims 1 to 8; and

25 b) determining the elimination of the chromophore or fluorophore qualitatively or quantitatively.


21. A method as claimed in claim 20, wherein the conversion is carried out in the presence of a hydrogen peroxide-cleaving enzyme and, where appropriate, in the presence of chloride ions.

30 22. A test kit comprising an electron donor system as claimed in any of claims 1 to 8.

35

40

45






FIG.2

3/10




Fig.3

4/10




Fig.4

5/10




Fig. 5

6/10





Fig.6

Fig. 7

—■— Influence of buffer on p-nitrophenol reduction
—●— Influence of buffer on Co(III)sepulchrate reduction
—▲— Influence of buffer on 12-pNCA/P450 BM-3 F87A activity








Fig.8

9/10



Absorption at 410 nm after 10 min [-]

Fig.9

10/10




Fig.10

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)